

Buprenorphine maintenance versus placebo or methadone dependence

The Cochrane Library

2014, CD002207

DOI: [10.1002/14651858.cd002207.pub4](https://doi.org/10.1002/14651858.cd002207.pub4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. <i>Drug and Alcohol Dependence</i> , 2003, 71, 295-302.	1.6	101
2	Whose Harm? Harm Reduction and the Shift to Coercion in UK Drug Policy. <i>Social Policy and Society</i> , 2004, 3, 333-342.	0.7	43
3	Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving. <i>Evidence-Based Mental Health</i> , 2004, 7, 54-54.	2.2	1
4	Jail Management of Arrestees/Inmates Enrolled in Community Methadone Maintenance Programs. <i>Journal of Urban Health</i> , 2004, 81, 645-654.	1.8	45
5	Buprenorphine in the treatment of opioid dependence. <i>European Neuropsychopharmacology</i> , 2004, 14, 209-216.	0.3	63
6	Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. <i>Drug and Alcohol Dependence</i> , 2004, 75, 37-45.	1.6	122
7	Brief report: Buprenorphine retention in primary care. <i>Journal of General Internal Medicine</i> , 2005, 20, 1038-1041.	1.3	156
8	Difficulties with buprenorphine. <i>Psychiatric Bulletin</i> , 2005, 29, 435-435.	0.3	1
9	Sublingual Buprenorphine and Methadone Maintenance Treatment: A Three-Year Follow-Up of Quality of Life Assessment. <i>Scientific World Journal, The</i> , 2005, 5, 452-468.	0.8	59
10	Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment. <i>Journal of Analytical Toxicology</i> , 2005, 29, 769-776.	1.7	41
11	Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence. <i>American Journal of Psychiatry</i> , 2005, 162, 340-349.	4.0	123
12	Palliative Care for Patient with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. <i>Journal of Palliative Medicine</i> , 2005, 8, 1248-1268.	0.6	11
13	A Randomised Trial of the Cost Effectiveness of Buprenorphine as an Alternative to Methadone Maintenance Treatment for Heroin Dependence in a Primary Care Setting. <i>Pharmacoeconomics</i> , 2005, 23, 77-91.	1.7	73
14	An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 321-329.	1.5	473
15	Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. <i>Journal of Substance Abuse Treatment</i> , 2005, 29, 307-312.	1.5	20
16	Determinants of methadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy. <i>Drug and Alcohol Dependence</i> , 2005, 79, 191-199.	1.6	9
17	Eficacia cl�nica de la buprenorfina. <i>Trastornos Adictivos</i> , 2005, 7, 23-26.	0.1	5
18	Paciente en programa de mantenimiento con metadona. <i>Trastornos Adictivos</i> , 2005, 7, 211-218.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Pharmaco-economics of community maintenance for opiate dependence: A review of evidence and methodology. <i>Drug and Alcohol Dependence</i> , 2006, 84, 28-39.	1.6	26
20	Buprenorphine Treatment: A Three-Year Prospective Study in Opioid-Addicted Patients of a Public Out-Patient Addiction Center in Milan. <i>American Journal on Addictions</i> , 2006, 15, 246-251.	1.3	10
21	Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients. <i>BMC Public Health</i> , 2006, 6, 216.	1.2	12
22	Buprenorphine: a potential new treatment option for opioid dependence. <i>Cmaj</i> , 2006, 174, 1835-1835.	0.9	14
23	Annals Journal Club: It's Time to Get RADICAL. <i>Annals of Family Medicine</i> , 2006, 4, 196-197.	0.9	88
24	Methadone Treatment in Clinical Practice in Italy: Need for Improvement. <i>European Addiction Research</i> , 2006, 12, 121-127.	1.3	13
25	Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. <i>Journal of Public Health</i> , 2007, 29, 350-357.	1.0	54
26	Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings. <i>Annals of Family Medicine</i> , 2007, 5, 146-150.	0.9	112
27	Efficacy of maintenance treatment with methadone for opioid dependence: A meta-analytical study. <i>Nordic Journal of Psychiatry</i> , 2007, 61, 288-295.	0.7	30
28	A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence. <i>American Journal of Psychiatry</i> , 2007, 164, 160-162.	4.0	144
29	Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2007, 5, 141-150.	0.4	2
30	Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. <i>Drug and Alcohol Dependence</i> , 2007, 90, 261-269.	1.6	85
31	Buprenorphine Reduces Alcohol Drinking Through Activation of the Nociceptin/Orphanin FQ-NOP Receptor System. <i>Biological Psychiatry</i> , 2007, 61, 4-12.	0.7	85
32	Antipsychotic medications for cocaine dependence. , 2007, , CD006306.		23
33	Opioides. , 2007, , 455-470.		0
34	The effects of buprenorphine on fentanyl withdrawal in rats. <i>Psychopharmacology</i> , 2007, 191, 931-941.	1.5	19
35	Preliminary Study of Buprenorphine and Bupropion for Opioid-Dependent Smokers. <i>American Journal on Addictions</i> , 2008, 17, 287-292.	1.3	32
36	Oral substitution treatments for opioid dependence. <i>Lancet, The</i> , 2008, 371, 2150-2151.	6.3	13

#	ARTICLE	IF	CITATIONS
37	Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice. <i>Annals of Internal Medicine</i> , 2008, 148, 662.	2.0	49
38	Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 195-197.	2.2	1
39	The Use Of Electronic Medical Records For Homeless Outreach. <i>Journal of Health Care for the Poor and Underserved</i> , 2008, 19, 1270-1281.	0.4	6
40	Characteristics of Primary Amphetamine Users in Sweden: A Criminal Justice Population Examined with the Addiction Severity Index. <i>European Addiction Research</i> , 2009, 15, 10-18.	1.3	22
41	United States Government Oversight and Regulation of Medication Assisted Treatment for the Treatment of Opioid Dependence. <i>Journal of Drug Policy Analysis</i> , 2009, 2, 1-23.	0.5	19
42	Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2009, 49, 1433-1440.	2.9	108
43	NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America. <i>Harm Reduction Journal</i> , 2009, 6, 2.	1.3	34
44	Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence. <i>American Journal on Addictions</i> , 2009, 18, 301-308.	1.3	50
45	An overview of principles of effective treatment of substance use disorders and their potential application to pregnant cigarette smokers. <i>Drug and Alcohol Dependence</i> , 2009, 104, S106-S114.	1.6	11
47	Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program. <i>Annals of Internal Medicine</i> , 2010, 152, 704.	2.0	99
48	Opioid substitution therapy in manipur and nagaland, north-east india: operational research in action. <i>Harm Reduction Journal</i> , 2010, 7, 29.	1.3	35
49	Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. <i>Substance Abuse and Rehabilitation</i> , 2010, 2010, 13.	1.6	38
50	Is Heroin-Assisted Treatment Effective for Patients with No Previous Maintenance Treatment? Results from a German Randomised Controlled Trial. <i>European Addiction Research</i> , 2010, 16, 124-130.	1.3	27
51	Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis. <i>European Addiction Research</i> , 2010, 16, 31-42.	1.3	15
52	Prevention of HIV Infection among Injection Drug Users in Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2010, 50, S114-S121.	2.9	84
53	Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. <i>BMJ: British Medical Journal</i> , 2010, 341, c5475-c5475.	2.4	250
54	Therapeutic Switch to Buprenorphine/Naloxone from Buprenorphine Alone. <i>Clinical Drug Investigation</i> , 2010, 30, 13-19.	1.1	9
55	Pituitary gland volume among heroin users stabilised on substitution pharmacotherapy. <i>Drug and Alcohol Dependence</i> , 2010, 110, 164-166.	1.6	11

#	ARTICLE	IF	CITATIONS
56	Safety and Efficacy of Buprenorphine/Naloxone in Opioid-Dependent Patients. <i>Clinical Drug Investigation</i> , 2010, 30, 21-26.	1.1	7
57	Neurological complications of alcohol and misuse of drugs. <i>Practical Neurology</i> , 2011, 11, 206-219.	0.5	34
58	Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 109-122.	1.5	29
60	Naltrexone extended-release injection: an option for the management of opioid abuse. <i>Substance Abuse and Rehabilitation</i> , 2011, 2, 219.	1.6	3
61	Screening, Brief Intervention, and Referral to Treatment (SBIRT): Toward a Public Health Approach to the Management of Substance Abuse. <i>Focus (American Psychiatric Publishing)</i> , 2011, 9, 130-148.	0.4	6
62	Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach. <i>Harm Reduction Journal</i> , 2011, 8, 31.	1.3	14
63	Prescription Pain Medication Dependence. <i>American Journal of Psychiatry</i> , 2011, 168, 466-471.	4.0	30
64	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 345, e5945-e5945.	3.0	363
65	Buprenorphine in TheTreatment of Heroin Addiction /. <i>Dusunen Adam</i> , 2012, , 93-100.	0.0	0
66	High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada. <i>Evidence-Based Mental Health</i> , 2012, 15, 9-9.	2.2	5
67	A Randomized Clinical Trial of Methadone Maintenance for Prisoners: Prediction of Treatment Entry and Completion in Prison. <i>Journal of Offender Rehabilitation</i> , 2012, 51, 222-238.	0.5	19
68	Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification. <i>Neuropsychiatry</i> , 2012, 2, 355-362.	0.4	0
69	Comparing buprenorphine induction experience with heroin and prescription opioid users. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 285-290.	1.5	21
70	Maintenance Medication for Opiate Addiction: The Foundation of Recovery. <i>Journal of Addictive Diseases</i> , 2012, 31, 207-225.	0.8	389
71	Agonist treatment in opioid use: Advances and controversy. <i>Asian Journal of Psychiatry</i> , 2012, 5, 125-131.	0.9	4
72	Evidence-based pharmacotherapy of illicit substance use disorders. , 0, , 235-261.		0
73	Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling. <i>Current Drug Abuse Reviews</i> , 2012, 5, 3-31.	3.4	94
74	Maintenance drugs to treat opioid dependence. <i>BMJ, The</i> , 2012, 344, e2823-e2823.	3.0	18

#	ARTICLE	IF	CITATIONS
75	Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. <i>Cmaj</i> , 2012, 184, E317-E328.	0.9	82
76	Italy's electronic health record system for opioid agonist treatment. <i>Journal of Substance Abuse Treatment</i> , 2013, 45, 190-195.	1.5	5
77	Managing Substance Dependence as a Chronic Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1132.	3.8	12
79	Future delivery of the Drug Interventions Programme: Do the benefits justify the costs?. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2013, 20, 816-820.	0.5	3
80	Chronic Care Management for Dependence on Alcohol and Other Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1156.	3.8	116
81	Responses of State Medicaid Programs to Buprenorphine Diversion. <i>JAMA Internal Medicine</i> , 2013, 173, 1571.	2.6	29
83	Impact of Physical Exercise on Substance Use Disorders: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e110728.	1.1	180
84	Predictors of Dropout from Inpatient Opioid Detoxification with Buprenorphine: A Chart Review. <i>Journal of Addiction</i> , 2014, 2014, 1-5.	0.9	11
85	Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 587.	1.0	35
86	Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2014, 4, 22902.	0.4	13
87	Role of Medication and Background Variables in Dropout from Opiate Withdrawal Treatment – A Retrospective Chart Review. <i>Journal of Alcoholism and Drug Dependence</i> , 2014, 03, .	0.2	0
88	Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: comparison of Indigenous and non-Indigenous Australians. <i>BMC Public Health</i> , 2014, 14, 920.	1.2	10
89	Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment. <i>Annals of General Psychiatry</i> , 2014, 13, 35.	1.2	23
90	Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 37.	1.0	8
91	Methadone Treatment for HIV Prevention–Feasibility, Retention, and Predictors of Attrition in Dar es Salaam, Tanzania: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 735-742.	2.9	37
92	Afghanistan has a sizeable problem with opioid use. <i>The Lancet Global Health</i> , 2014, 2, e557-e558.	2.9	3
93	Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence. <i>Psychiatric Services</i> , 2014, 65, 158-170.	1.1	174
94	A comparative study of opioid substitution therapy utilisation among opioid–dependent men and women. <i>Drug and Alcohol Review</i> , 2014, 33, 499-505.	1.1	3

#	ARTICLE	IF	CITATIONS
95	Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment—a case register analysis. <i>Harm Reduction Journal</i> , 2014, 11, 23.	1.3	4
96	Improving Care for Hospitalized, Opioid-Dependent Patients. <i>JAMA Internal Medicine</i> , 2014, 174, 1377.	2.6	1
97	Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status. <i>Journal of Drug Issues</i> , 2014, 44, 69-82.	0.6	13
98	Execution of control among “non-compliant”, imprisoned individuals in opioid maintenance treatment. <i>International Journal of Drug Policy</i> , 2014, 25, 480-485.	1.6	9
99	Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. <i>Drug and Alcohol Dependence</i> , 2014, 142, 139-145.	1.6	7
100	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	1.6	14
101	Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use—buprenorphine/naloxone treatment and recovery in a surgical patient. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014207458-bcr2014207458.	0.2	11
102	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. <i>The Cochrane Library</i> , 0, , .	1.5	1
103	OR06-5 * WHEN HIGHER DOSES IN OPIOID REPLACEMENT TREATMENT ARE STILL INADEQUATE - ASSOCIATION TO MULTIDIMENSIONAL ILLNESS SEVERITY: A COHORT STUDY. <i>Alcohol and Alcoholism</i> , 2014, 49, i44-i44.	0.9	0
104	The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence. <i>Health Services Research</i> , 2014, 49, n/a-n/a.	1.0	35
106	Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002–11. <i>Health Affairs</i> , 2015, 34, 1028-1034.	2.5	138
107	Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 10140.	1.6	16
108	Dopamine agonists for the treatment of cocaine dependence. <i>The Cochrane Library</i> , 2015, 2015, CD003352.	1.5	55
109	The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 644-654.	0.6	65
110	Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. <i>Trials</i> , 2015, 16, 475.	0.7	33
111	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e43-e48.	0.9	19
112	Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs. <i>American Journal on Addictions</i> , 2015, 24, 368-373.	1.3	7
113	Factors associated with willingness to take extended release naltrexone among injection drug users. <i>Addiction Science & Clinical Practice</i> , 2015, 10, 12.	1.2	27

#	ARTICLE	IF	CITATIONS
114	Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England. <i>Addiction</i> , 2015, 110, 1321-1329.	1.7	26
116	A Window of Opportunity: Maximizing the Effectiveness of New HCV Regimens in the United States With the Expansion of the Affordable Care Act. <i>American Journal of Public Health</i> , 2015, 105, 457-463.	1.5	7
117	Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. <i>Pharmacotherapy</i> , 2015, 35, 670-680.	1.2	31
118	Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. <i>Milbank Quarterly</i> , 2015, 93, 561-583.	2.1	89
119	A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. <i>Addiction</i> , 2015, 110, 1975-1984.	1.7	29
120	The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders. <i>American Journal on Addictions</i> , 2015, 24, 722-731.	1.3	15
121	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. <i>American Journal on Addictions</i> , 2015, 24, 667-675.	1.3	25
122	“Sub is a weird drug:” A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms. <i>American Journal on Addictions</i> , 2015, 24, 403-409.	1.3	27
123	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX). <i>Journal of Addiction Medicine</i> , 2015, 9, 238-243.	1.4	39
124	Attitudes towards Hepatitis C and Treatment Willingness in Injection Drug Users: A Follow-up Interview Study. <i>Journal of Alcoholism and Drug Dependence</i> , 2015, 03, .	0.2	0
125	New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone. <i>Substance Abuse and Rehabilitation</i> , 2015, 6, 1.	1.6	41
126	Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy. <i>Journal of Addiction Research & Therapy</i> , 2015, 06, .	0.2	12
127	Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015210239.	0.2	7
128	Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia. <i>Journal of Substance Abuse Treatment</i> , 2015, 54, 29-36.	1.5	18
129	Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment. <i>Substance Abuse</i> , 2015, 36, 155-160.	1.1	30
130	A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report. <i>Journal of Dual Diagnosis</i> , 2015, 11, 248-257.	0.7	65
131	Short term health-related quality of life improvement during opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2015, 157, 121-128.	1.6	39
132	Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S169-S175.	0.9	28

#	ARTICLE	IF	CITATIONS
133	Gender Considerations in Addiction: Implications for Treatment. Current Treatment Options in Psychiatry, 2015, 2, 326-338.	0.7	42
134	Preferences for Aftercare Among Persons Seeking Short-Term Opioid Detoxification. Journal of Substance Abuse Treatment, 2015, 59, 99-103.	1.5	26
135	Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy. Journal of Substance Abuse Treatment, 2015, 56, 48-53.	1.5	30
136	A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine. Drug and Alcohol Dependence, 2015, 147, 243-250.	1.6	41
137	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug and Alcohol Dependence, 2015, 147, 122-129.	1.6	22
138	Drug and alcohol addiction: new pharmacotherapies. BJ Psych Advances, 2015, 21, 33-41.	0.5	4
139	Striatal dopamine D1 and D2 receptors are differentially regulated following buprenorphine or methadone treatment. Psychopharmacology, 2015, 232, 1527-1533.	1.5	9
140	Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addiction Science & Clinical Practice, 2015, 10, 2.	1.2	66
141	Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility. Addictive Behaviors, 2015, 51, 136-142.	1.7	31
142	Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Drug and Alcohol Dependence, 2015, 152, 164-169.	1.6	8
143	The effects of continuing care on emerging adult outcomes following residential addiction treatment. Drug and Alcohol Dependence, 2015, 153, 207-214.	1.6	24
144	Circumspectives: The Replacements. Neuropsychopharmacology, 2015, 40, 1813-1814.	2.8	1
145	Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. Journal of Psychoactive Drugs, 2015, 47, 149-157.	1.0	59
146	Treating Tobacco Use Disorder in Pregnant Women in Medication-Assisted Treatment for an Opioid Use Disorder: A Systematic Review. Journal of Substance Abuse Treatment, 2015, 52, 40-47.	1.5	48
147	Increasing access to opioid maintenance treatment: The role of primary care in France. International Journal of Drug Policy, 2015, 26, 434-435.	1.6	3
148	A review of pharmacogenetic studies of substance-related disorders. Drug and Alcohol Dependence, 2015, 152, 1-14.	1.6	29
149	Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers. Journal of Urban Health, 2015, 92, 193-213.	1.8	49
150	Chronic Pain and Depression Among Primary Care Patients Treated with Buprenorphine. Journal of General Internal Medicine, 2015, 30, 935-941.	1.3	32

#	ARTICLE	IF	CITATIONS
151	Treatment Strategies for Cannabis Use in Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 168-181.	0.7	1
152	Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 122-135.	0.7	2
153	Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes. <i>Journal of Substance Abuse Treatment</i> , 2015, 52, 48-57.	1.5	122
154	Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. <i>Harm Reduction Journal</i> , 2015, 12, 1.	1.3	44
155	Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2015, 10, 13.	1.0	42
156	Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy. <i>Scientific Reports</i> , 2015, 5, 9708.	1.6	8
157	Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared with Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence. <i>Substance Abuse</i> , 2015, 36, 226-231.	1.1	48
158	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. <i>Lancet Psychiatry</i> , 2015, 2, 901-908.	3.7	106
159	Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration. <i>Addiction</i> , 2015, 110, 1468-1475.	1.7	54
160	Substance Use in the Perinatal Period. <i>Current Psychiatry Reports</i> , 2015, 17, 91.	2.1	103
161	Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 89-95.	1.5	63
162	Commentary on Burns <i>et al</i> . (2015): Retention in buprenorphine treatment. <i>Addiction</i> , 2015, 110, 656-657.	1.7	6
163	Prenatally buprenorphine-exposed children: health to 3 years of age. <i>European Journal of Pediatrics</i> , 2015, 174, 1525-1533.	1.3	16
164	Care of the Homeless Patient. <i>Medical Clinics of North America</i> , 2015, 99, 1017-1038.	1.1	6
165	Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 75-80.	1.5	98
166	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , 2015, 154, 38-45.	1.6	78
167	Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 57-62.	1.5	32
168	Substance use during pregnancy. <i>F1000Research</i> , 2016, 5, 887.	0.8	179

#	ARTICLE	IF	CITATIONS
169	Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. <i>Substance Abuse and Rehabilitation</i> , 2016, 7, 81.	1.6	10
170	Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method”. <i>Substance Abuse and Rehabilitation</i> , 2016, Volume 7, 99-105.	1.6	146
171	Methadone Usage, Misuse, and Addiction Processes. , 2016, , 399-406.		0
172	Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study. <i>Journal of Addiction</i> , 2016, 2016, 1-8.	0.9	5
173	Dihydrocodeine for detoxification and maintenance treatment in illicit opiate-dependent individuals. <i>The Cochrane Library</i> , 2016, , .	1.5	1
174	Random Forest Segregation of Drug Responses May Define Regions of Biological Significance. <i>Frontiers in Computational Neuroscience</i> , 2016, 10, 21.	1.2	4
175	Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 222-228.	0.7	21
176	Pharmacotherapy for Substance Use Disorders in Youths. <i>Journal of Child and Adolescent Substance Abuse</i> , 2016, 25, 292-316.	0.5	13
177	Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial. <i>Addiction</i> , 2016, 111, 903-912.	1.7	26
178	Protective factors associated with short-term cessation of injection drug use among a Canadian cohort of people who inject drugs. <i>Drug and Alcohol Review</i> , 2016, 35, 620-627.	1.1	9
179	Substance Use Disorders. <i>Annals of Internal Medicine</i> , 2016, 164, ITC49.	2.0	17
180	Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications. <i>Health Affairs</i> , 2016, 35, 2289-2296.	2.5	89
181	Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose. <i>Annals of Internal Medicine</i> , 2016, 164, 1.	2.0	156
182	Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000-2010. <i>BMC Psychiatry</i> , 2016, 16, 168.	1.1	15
183	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <i>Postgraduate Medical Journal</i> , 2016, 92, 356-363.	0.9	22
184	Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults. <i>Addictive Behaviors</i> , 2016, 60, 137-143.	1.7	29
185	Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators. <i>AIDS and Behavior</i> , 2016, 20, 2950-2960.	1.4	37
186	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. <i>Drug and Alcohol Dependence</i> , 2016, 162, 190-198.	1.6	10

#	ARTICLE	IF	CITATIONS
187	Optimizing Psychosocial Support during Office-Based Buprenorphine Treatment in Primary Care: Patients'™ Experiences and Preferences. <i>Substance Abuse</i> , 2016, 37, 70-75.	1.1	38
188	Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder. <i>Journal of Substance Abuse Treatment</i> , 2016, 67, 30-37.	1.5	13
189	Economic Evaluations of Opioid Use Disorder Interventions. <i>Pharmacoeconomics</i> , 2016, 34, 863-887.	1.7	79
190	One-Year Follow-Up of Heroin-Dependent Adolescents Treated with Buprenorphine/Naloxone for the First Time in a Substance Treatment Unit. <i>Journal of Substance Abuse Treatment</i> , 2016, 67, 1-8.	1.5	11
191	Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 214-217.	1.0	16
192	Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. <i>Drug and Alcohol Dependence</i> , 2016, 164, 14-21.	1.6	146
193	Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film. <i>Journal of Addiction Medicine</i> , 2016, 10, 124-130.	1.4	12
194	Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence. <i>JAMA Psychiatry</i> , 2016, 73, 447.	6.0	168
195	“œl Kicked the Hard Way. I Got Incarcerated.”Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments. <i>Journal of Substance Abuse Treatment</i> , 2016, 62, 49-54.	1.5	42
196	Pharmacotherapy for Substance Use Disorders. <i>Medical Clinics of North America</i> , 2016, 100, 891-910.	1.1	40
197	Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. <i>Journal of Substance Abuse Treatment</i> , 2016, 66, 48-53.	1.5	80
198	Buprenorphine Prescribing: To Expand or Not to Expand. <i>Journal of Psychiatric Practice</i> , 2016, 22, 183-192.	0.3	23
199	Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007“2013. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 58-63.	1.5	2
200	Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization. <i>Journal of Substance Abuse Treatment</i> , 2016, 68, 68-73.	1.5	30
201	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	0.8	49
202	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. <i>Contemporary Clinical Trials</i> , 2016, 51, 34-43.	0.8	28
203	Alcohol and Opioid Use Disorder in Older Adults: Neglected and Treatable Illnesses. <i>Current Psychiatry Reports</i> , 2016, 18, 87.	2.1	51
204	New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening. <i>Human Psychopharmacology</i> , 2016, 31, 44-52.	0.7	46

#	ARTICLE	IF	CITATIONS
205	Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. <i>Addiction</i> , 2016, 111, 298-308.	1.7	124
206	A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 50-57.	1.5	11
207	Interest in Extended Release Naltrexone among Opioid Users. <i>European Addiction Research</i> , 2016, 22, 301-305.	1.3	5
208	An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders. <i>Cmaj</i> , 2016, 188, 1208-1209.	0.9	15
210	Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All. <i>Neonatal Network: NN</i> , 2016, 35, 314-320.	0.1	9
211	Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. <i>Depression and Anxiety</i> , 2016, 33, 895-906.	2.0	123
212	Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. <i>BMJ Open</i> , 2016, 6, e011774.	0.8	38
213	Access to substance use treatment among young adults who use prescription opioids non-medically. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 38.	1.0	40
214	Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol. <i>Systematic Reviews</i> , 2016, 5, 139.	2.5	12
215	Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the "other epidemic". <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 33.	1.0	11
216	Opioid Use Disorder in Pregnancy. <i>Obstetrics and Gynecology</i> , 2016, 128, 4-10.	1.2	156
217	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. <i>Journal of Addiction Medicine</i> , 2016, 10, 300-308.	1.4	57
218	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	1.5	148
219	Which medications are suitable for agonist drug maintenance?. <i>Addiction</i> , 2016, 111, 767-774.	1.7	28
220	Attitudes towards a maintenance (-agonist) treatment approach in high-dose benzodiazepine-dependent patients: a qualitative study. <i>Harm Reduction Journal</i> , 2016, 13, 1.	1.3	32
221	Primary care physicians' perspectives on the prescription opioid epidemic. <i>Drug and Alcohol Dependence</i> , 2016, 165, 61-70.	1.6	95
222	Abstinence at Successful Discharge in Publicly Funded Addiction Health Services. <i>Journal of Behavioral Health Services and Research</i> , 2016, 43, 661-675.	0.6	4
223	Treatment of prescription opioid disorders in Canada: looking at the "other epidemic". <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 12.	1.0	28

#	ARTICLE	IF	CITATIONS
224	The opiate dosage adequacy scale for identification of the right methadone dose—a prospective cohort study. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 15.	1.0	7
225	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 18.	1.0	18
226	Dependence on Over the Counter (OTC) Codeine Containing Analgesics: Treatment and Recovery with Buprenorphine Naloxone. <i>International Journal of Mental Health and Addiction</i> , 2016, 14, 873-883.	4.4	10
227	Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France. <i>Drug and Alcohol Dependence</i> , 2016, 162, 99-106.	1.6	18
228	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. <i>Addiction</i> , 2016, 111, 695-705.	1.7	165
229	Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. <i>Drug and Alcohol Dependence</i> , 2016, 160, 112-118.	1.6	121
230	Opioid Maintenance Treatment - A Call for a Joint European Quality Care Approach. <i>European Addiction Research</i> , 2016, 22, 36-51.	1.3	12
231	Community Correctional Agents™ Views of Medication-Assisted Treatment: Examining Their Influence on Treatment Referrals and Community Supervision Practices. <i>Substance Abuse</i> , 2016, 37, 127-133.	1.1	38
232	Factors Associated with Buprenorphine versus Methadone use in Pregnancy. <i>Substance Abuse</i> , 2016, 37, 550-557.	1.1	34
233	Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania. <i>International Journal of Drug Policy</i> , 2016, 30, 74-81.	1.6	18
234	Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients. <i>BMC Family Practice</i> , 2016, 17, 24.	2.9	5
235	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 70-75.	1.1	7
236	Antipsychotic medications for cocaine dependence. <i>The Cochrane Library</i> , 2016, 2016, CD006306.	1.5	56
237	A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 394-400.	2.1	9
238	New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine. <i>Current Pain and Headache Reports</i> , 2016, 20, 16.	1.3	48
239	CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1624.	3.8	3,146
240	Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification. <i>Journal of Substance Abuse Treatment</i> , 2016, 64, 44-46.	1.5	8
241	Antagonist Models for Relapse Prevention and Reducing HIV Risk. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 401-407.	2.1	2

#	ARTICLE	IF	CITATIONS
242	Policies Related to Opioid Agonist Therapy for Opioid use Disorders: The Evolution of State Policies from 2004 to 2013. <i>Substance Abuse</i> , 2016, 37, 63-69.	1.1	59
243	Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 79-87.e1.	0.6	23
244	Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update. <i>American Journal of Psychiatry</i> , 2016, 173, 18-26.	4.0	204
245	Retention in medication-assisted treatment for opiate dependence: A systematic review. <i>Journal of Addictive Diseases</i> , 2016, 35, 22-35.	0.8	338
246	The potential utility of some legal highs in CNS disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 267-274.	2.5	12
247	Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation. <i>Journal of Rural Health</i> , 2017, 33, 102-109.	1.6	35
248	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017, 36, 311-316.	1.1	3
249	A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. <i>Drug and Alcohol Dependence</i> , 2017, 172, 34-42.	1.6	52
250	Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. <i>Molecular Psychiatry</i> , 2017, 22, 346-352.	4.1	85
251	The association of psychedelic use and opioid use disorders among illicit users in the United States. <i>Journal of Psychopharmacology</i> , 2017, 31, 606-613.	2.0	49
252	Opioid Use Disorder: A Desperate Need for Novel Treatments. <i>Biological Psychiatry</i> , 2017, 81, e43-e45.	0.7	5
253	Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision. <i>British Journal of General Practice</i> , 2017, 67, e267-e273.	0.7	9
254	Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence. <i>New England Journal of Medicine</i> , 2017, 376, 1000-1001.	13.9	5
255	Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. <i>Drug and Alcohol Dependence</i> , 2017, 174, 181-191.	1.6	29
256	Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. <i>Addiction</i> , 2017, 112, 1408-1418.	1.7	130
257	Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. <i>Psychiatry Research</i> , 2017, 250, 210-216.	1.7	36
258	The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2017, 102, F183-F187.	1.4	39
259	Quality of life as an outcome of opioid use disorder treatment: A systematic review. <i>Journal of Substance Abuse Treatment</i> , 2017, 76, 88-93.	1.5	50

#	ARTICLE	IF	CITATIONS
260	Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 160-168.	1.0	2
261	Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study. <i>European Addiction Research</i> , 2017, 23, 61-70.	1.3	11
262	QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2274-2282.	1.1	30
263	Treating the Symptom but Not the Underlying Disease in Infective Endocarditis. <i>JAMA Internal Medicine</i> , 2017, 177, 1026.	2.6	11
264	Addiction consultation services – Linking hospitalized patients to outpatient addiction treatment. <i>Journal of Substance Abuse Treatment</i> , 2017, 79, 1-5.	1.5	161
265	Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder. <i>Journal of Dual Diagnosis</i> , 2017, 13, 201-212.	0.7	42
266	The relationship between diversion-related attitudes and sharing and selling buprenorphine. <i>Journal of Substance Abuse Treatment</i> , 2017, 78, 43-47.	1.5	22
267	Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis. <i>International Journal of Drug Policy</i> , 2017, 45, 1-8.	1.6	18
268	Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2017, 25, 223-233.	1.3	0
269	Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 102-110.	1.0	19
270	Buprenorphine oral lyophilisate (Espranor®) in the substitution treatment of opioid dependence: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 241-248.	0.3	2
271	Computer-aided design and synthesis of a highly selective molecularly imprinted polymer for the extraction and determination of buprenorphine in biological fluids. <i>Journal of Separation Science</i> , 2017, 40, 3175-3182.	1.3	14
272	Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs. <i>Addictive Behaviors</i> , 2017, 73, 129-132.	1.7	26
273	Update on Barriers to Pharmacotherapy for Opioid Use Disorders. <i>Current Psychiatry Reports</i> , 2017, 19, 35.	2.1	119
274	Targeting practitioners: A review of guidelines, training, and policy in pain management. <i>Drug and Alcohol Dependence</i> , 2017, 173, S22-S30.	1.6	42
275	The Prescription Opioid Addiction Treatment Study: What have we learned. <i>Drug and Alcohol Dependence</i> , 2017, 173, S48-S54.	1.6	50
276	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002025.	1.5	66
277	Pharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 102-115.	0.7	2

#	ARTICLE	IF	CITATIONS
278	Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study. <i>The Lancet Global Health</i> , 2017, 5, e198-e207.	2.9	57
279	Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 666-669.	1.0	17
280	Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 458-463.	0.6	19
281	Primary Care-Based Models for the Treatment of Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2017, 166, 268.	2.0	224
282	The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. <i>American Journal of Psychiatry</i> , 2017, 174, 738-747.	4.0	167
283	Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?. <i>Journal of the International AIDS Society</i> , 2017, 20, 22146.	1.2	126
284	Social-demographic shift in drug users at the first-ever- methadone maintenance treatment in Wuhan, China. <i>Scientific Reports</i> , 2017, 7, 11446.	1.6	5
285	Why People Who Inject Drugs Voluntarily Transition Off Methadone in Ukraine. <i>Qualitative Health Research</i> , 2017, 27, 2057-2070.	1.0	16
286	Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18-months Retention in an Office-Based Treatment Program. <i>Substance Abuse: Research and Treatment</i> , 2017, 11, 117822181773132.	0.5	0
287	A police-led addiction treatment referral program in Gloucester, MA: Implementation and participants' experiences. <i>Journal of Substance Abuse Treatment</i> , 2017, 82, 41-47.	1.5	39
288	Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. <i>World Psychiatry</i> , 2017, 16, 299-307.	4.8	160
289	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. <i>JAMA Psychiatry</i> , 2017, 74, 1197.	6.0	200
290	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. <i>International Journal of Drug Policy</i> , 2017, 49, 32-40.	1.6	87
291	Deaths from Opioid Overdosing: Implications of Coroners' Inquest Reports 2008-2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study. <i>Pain and Therapy</i> , 2017, 6, 203-215.	1.5	32
292	Ability to join the workforce and work productivity among drug users under methadone maintenance treatment in a mountainous area of Northern Vietnam: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e016153.	0.8	8
293	Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. <i>Drug and Alcohol Dependence</i> , 2017, 173, S55-S64.	1.6	34
294	Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. <i>Drug and Alcohol Dependence</i> , 2017, 178, 512-518.	1.6	79
295	Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. <i>Drug and Alcohol Dependence</i> , 2017, 179, 362-369.	1.6	15

#	ARTICLE	IF	CITATIONS
296	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine+Naloxone and Methadone. <i>Journal of Addiction Medicine</i> , 2017, 11, 63-69.	1.4	54
297	Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. <i>International Journal of Drug Policy</i> , 2017, 48, 44-53.	1.6	20
298	Impact of a Mandated Change in Buprenorphine Formulation. <i>Journal of Addiction Medicine</i> , 2017, 11, 435-439.	1.4	2
300	Canada Is in Urgent Need to Expand Opioid Agonist Treatment. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 442-443.	0.9	3
301	Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review. <i>International Journal of Mental Health and Addiction</i> , 2017, 15, 452-469.	4.4	56
302	Development and evaluation of a community-based buprenorphine treatment intervention. <i>Harm Reduction Journal</i> , 2017, 14, 23.	1.3	13
303	Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 3.	1.0	46
304	Implementation of methadone therapy for opioid use disorder in Russia—a modeled cost-effectiveness analysis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 4.	1.0	20
305	Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders. <i>Psychiatric Services</i> , 2017, 68, 295-298.	1.1	8
306	Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. <i>Addiction</i> , 2017, 112, 386-387.	1.7	20
307	Care of the Patient Who Misuses Drugs. , 2017, , 773-785.		0
308	“Don’t Judge a Book by Its Cover”: A Qualitative Study of Methadone Patients’ Experiences of Stigma. <i>Substance Abuse: Research and Treatment</i> , 2017, 11, 117822181668508.	0.5	77
309	Decision-Based Disorders. <i>Policy Insights From the Behavioral and Brain Sciences</i> , 2017, 4, 49-56.	1.4	5
310	Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. <i>BMJ: British Medical Journal</i> , 2017, 357, j1947.	2.4	17
311	Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. <i>BMJ: British Medical Journal</i> , 2017, 357, j1550.	2.4	1,076
312	Toward the Identification of a Specific Psychopathology of Substance Use Disorders. <i>Frontiers in Psychiatry</i> , 2017, 8, 68.	1.3	9
313	Malmö Treatment Referral and Intervention Study—High 12-Month Retention Rates in Patients Referred from Syringe Exchange to Methadone or Buprenorphine/Naloxone Treatment. <i>Frontiers in Psychiatry</i> , 2017, 8, 161.	1.3	7
314	Advances in the delivery of buprenorphine for opioid dependence. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2493-2505.	2.0	46

#	ARTICLE	IF	CITATIONS
315	Evaluating the impact of Affordable Care Act repeal on America's opioid epidemic. <i>PLoS Medicine</i> , 2017, 14, e1002380.	3.9	6
316	Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon. <i>Harm Reduction Journal</i> , 2017, 14, 78.	1.3	7
317	Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 46.	1.0	14
318	Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. <i>Implementation Science</i> , 2017, 12, 135.	2.5	11
319	Barriers and facilitators to implementing addiction medicine fellowships: a qualitative study with fellows, medical students, residents and preceptors. <i>Addiction Science & Clinical Practice</i> , 2017, 12, 21.	1.2	10
320	Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. <i>BMC Psychiatry</i> , 2017, 17, 245.	1.1	49
321	Infectious Disease (ID) Learning Unit: What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw251.	0.4	3
322	Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. <i>Journal of Addiction Medicine</i> , 2018, 12, 170-183.	1.4	45
323	Psychiatry and Pain Management: at the Intersection of Chronic Pain and Mental Health. <i>Current Psychiatry Reports</i> , 2018, 20, 12.	2.1	62
324	Management of opioid use disorders: a national clinical practice guideline. <i>Cmaj</i> , 2018, 190, E247-E257.	0.9	297
325	Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis. <i>Drug and Alcohol Dependence</i> , 2018, 185, 322-327.	1.6	60
326	The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. <i>Addiction</i> , 2018, 113, 1461-1476.	1.7	83
327	Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults. <i>Psychiatric Services</i> , 2018, 69, 768-776.	1.1	61
328	Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. <i>Journal of Psychoactive Drugs</i> , 2018, 50, 256-265.	1.0	32
329	Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. <i>Addiction</i> , 2018, 113, 1264-1273.	1.7	33
330	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 69, 21-27.	0.8	22
331	ENDING THE OPIOID EPIDEMIC REQUIRES A HISTORIC INVESTMENT IN MEDICATION-ASSISTED TREATMENT. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 431-438.	1.1	20
332	Quality of life and well-being following inpatient and partial hospitalization treatment for opioid use disorder. <i>Archives of Psychiatric Nursing</i> , 2018, 32, 505-509.	0.7	7

#	ARTICLE	IF	CITATIONS
333	Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 431-440.	1.1	24
334	Extended-release injectable naltrexone for opioid use disorder: a systematic review. <i>Addiction</i> , 2018, 113, 1188-1209.	1.7	148
335	At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care" Substance Use and Misuse, 2018, 53, 301-310.	0.7	35
336	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. <i>The Cochrane Library</i> , 2018, 2018, CD011057.	1.5	15
337	Increasing diversion of methadone in Vancouver, Canada, 2005-2015. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 10-16.	1.5	10
338	Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users. <i>Journal of Substance Abuse Treatment</i> , 2018, 86, 30-35.	1.5	30
339	Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. <i>Journal of Substance Abuse Treatment</i> , 2018, 86, 17-25.	1.5	25
340	State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. <i>Psychiatric Services</i> , 2018, 69, 448-455.	1.1	9
341	A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. <i>Substance Use and Misuse</i> , 2018, 53, 220-229.	0.7	66
342	Drug-Use Disorders. , 0, , 243-262.		3
343	Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury. <i>JAMA Psychiatry</i> , 2018, 75, 649.	6.0	4
344	Characteristics and experiences of buprenorphine-naloxone use among polysubstance users. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 595-603.	1.1	13
345	Are patients' pejorative representations of buprenorphine associated with their level of addiction and of misuse?. <i>Drug and Alcohol Dependence</i> , 2018, 188, 10-15.	1.6	1
346	Perceptions and practices addressing diversion among US buprenorphine prescribers. <i>Drug and Alcohol Dependence</i> , 2018, 186, 147-153.	1.6	38
347	Substance use in pregnancy: The medical challenge. <i>Obstetric Medicine</i> , 2018, 11, 54-66.	0.5	36
348	A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. <i>Pharmacogenomics Journal</i> , 2018, 18, 173-179.	0.9	23
349	Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 49-55.	1.5	86
350	Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack. <i>Addictive Behaviors</i> , 2018, 77, 210-216.	1.7	16

#	ARTICLE	IF	CITATIONS
351	Addressing Host Factors: Primary, Secondary, and Tertiary Prevention of Opioid Dependence. , 2018, , 265-290.		1
352	Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. <i>Addiction</i> , 2018, 113, 656-667.	1.7	45
353	Why use Group Visits for Opioid use Disorder Treatment in Primary Care? A Patient-Centered Qualitative Study. <i>Substance Abuse</i> , 2018, 39, 52-58.	1.1	20
354	Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. <i>Neuropsychopharmacology</i> , 2018, 43, 116-141.	2.8	30
355	A statewide evaluation of seven strategies to reduce opioid overdose in North Carolina. <i>Injury Prevention</i> , 2018, 24, 48-54.	1.2	26
356	Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder. <i>Mindfulness</i> , 2018, 9, 423-429.	1.6	5
357	A Case of Opioid Overdose and Subsequent Death After Medically Supervised Withdrawal: The Problematic Role of Rapid Tapers for Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2018, 12, 80-83.	1.4	13
358	Pharmacogenetics of Methadone Response. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 57-78.	1.6	20
359	Effect of initiating drug treatment on the risk of drug-related poisoning death and acquisitive crime among offending heroin users. <i>International Journal of Drug Policy</i> , 2018, 51, 42-51.	1.6	5
360	Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio. <i>Journal of Addiction Medicine</i> , 2018, 12, 85-91.	1.4	4
361	Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids. <i>American Journal of Perinatology</i> , 2018, 35, 405-412.	0.6	26
362	Buprenorphine in Neonatal Abstinence Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 112-119.	2.3	21
363	Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 309-318.	6.3	502
364	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV [®] substance use disorder treatment centers and RADARSA [®] System Poison Centers. <i>Journal of Substance Abuse Treatment</i> , 2018, 84, 42-49.	1.5	13
365	Utilization of Buprenorphine and Methadone among Opioid users who Inject Drugs. <i>Substance Abuse</i> , 2018, 39, 83-88.	1.1	26
366	A review of the complexities of working effectively with people being prescribed both antipsychotic medications and opioid substitution therapy. <i>Drugs: Education, Prevention and Policy</i> , 2018, 25, 1-12.	0.8	4
367	Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. <i>Obstetrics and Gynecology</i> , 2018, 132, 466-474.	1.2	209
368	Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia. <i>Journal of Addictive Diseases</i> , 2018, 37, 1-4.	0.8	9

#	ARTICLE	IF	CITATIONS
369	Health Related Quality of Life in Individuals Transferred from a Needle Exchange Program and Starting Opioid Agonist Treatment. <i>Journal of Addiction</i> , 2018, 2018, 1-7.	0.9	6
370	Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services. <i>BMC Health Services Research</i> , 2018, 18, 911.	0.9	8
371	Improving Rural Access to Opioid Treatment Programs. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 437-439.	0.4	16
372	"Real World" Factors Influencing Dropout from Opiate Treatment with Methadone and Buprenorphine. <i>Journal of Addiction Research & Therapy</i> , 2018, 09, .	0.2	1
373	Use of Tramadol for Management of Opioid Use Disorders: Rationale and Recommendations. <i>Journal of Neurosciences in Rural Practice</i> , 2018, 09, 397-403.	0.3	9
374	Analyzing national and state opioid abuse treatment completion with multilevel modeling. , 2018, , .		4
375	The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. <i>Journal of Addiction Medicine</i> , 2018, 12, 459-465.	1.4	66
376	Histopathological study of liver tissue due to methadone consumption and its effect on liver enzymes and inflammatory indices in rat. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3785-3795.	2.0	4
377	Comorbid opioid use is undertreated among forensic patients with schizophrenia. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2018, 13, 39.	1.0	8
378	Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. <i>Addiction Science & Clinical Practice</i> , 2018, 13, 25.	1.2	33
379	Pharmacotherapy for opioid addiction in community corrections. <i>International Review of Psychiatry</i> , 2018, 30, 117-135.	1.4	8
380	The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic. <i>Harm Reduction Journal</i> , 2018, 15, 60.	1.3	11
381	A Public Health Strategy for the Opioid Crisis. <i>Public Health Reports</i> , 2018, 133, 24S-34S.	1.3	156
382	Empirical Studies Addressing the Opioid Epidemic: An Urgent Call for Research. <i>Substance Abuse: Research and Treatment</i> , 2018, 12, 117822181878429.	0.5	7
383	Microscopes and Telescopes: the Societal Impact of Substance Use Disorder Treatment. <i>American Journal of Psychiatry</i> , 2018, 175, 925-926.	4.0	0
384	High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. <i>Addiction</i> , 2018, 113, 2250-2258.	1.7	48
385	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	1.6	12
386	Time to Change the Way We Approach Opioid Use Disorder: A Challenge to the Status Quo. <i>Annals of Internal Medicine</i> , 2018, 169, 652.	2.0	3

#	ARTICLE	IF	CITATIONS
387	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Psychiatry</i> , 2018, 5, 987-1012.	3.7	885
388	Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. <i>Journal of Medical Toxicology</i> , 2018, 14, 306-322.	0.8	56
389	Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. <i>Journal of Substance Abuse Treatment</i> , 2018, 95, 9-17.	1.5	141
390	Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. <i>Journal of Substance Abuse Treatment</i> , 2018, 94, 55-59.	1.5	30
391	Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes. <i>Drug and Alcohol Dependence</i> , 2018, 188, 232-238.	1.6	11
392	Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. <i>JAMA Internal Medicine</i> , 2018, 178, 764.	2.6	148
393	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	1.6	18
394	A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid use Disorders among Medicaid Enrollees. <i>Substance Abuse</i> , 2018, 39, 419-425.	1.1	87
395	Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development. <i>Pharmacological Reviews</i> , 2018, 70, 661-683.	7.1	73
396	The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder. <i>Addictive Behaviors Reports</i> , 2018, 7, 82-89.	1.0	1
397	Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. <i>American Journal of Psychiatry</i> , 2018, 175, 970-978.	4.0	51
398	Italian psychiatry. <i>International Review of Psychiatry</i> , 2018, 30, 117-117.	1.4	1
399	A Dissemination and Implementation Science Approach to the Epidemic of Opioid Use Disorder in the United States. <i>Current HIV/AIDS Reports</i> , 2018, 15, 359-370.	1.1	11
400	Opioids and Cardiac Arrhythmia: A Literature Review. <i>Medical Principles and Practice</i> , 2018, 27, 401-414.	1.1	108
401	Community strengths in addressing opioid use in Northeastern Ontario. <i>Canadian Journal of Public Health</i> , 2018, 109, 219-222.	1.1	8
402	Mechanisms of Behavior Change in 12-Step Approaches to Recovery in Young Adults. <i>Current Addiction Reports</i> , 2018, 5, 134-145.	1.6	10
403	Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting. <i>Addiction Science & Clinical Practice</i> , 2018, 13, 3.	1.2	6
404	Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 604-610.	1.1	8

#	ARTICLE	IF	CITATIONS
405	Telemedicine's Role in Addressing the Opioid Epidemic. Mayo Clinic Proceedings, 2018, 93, 1177-1180.	1.4	35
406	Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. CNS Drugs, 2018, 32, 875-882.	2.7	7
407	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. Annals of Internal Medicine, 2018, 169, 137.	2.0	680
408	Medicaid Benefits For Addiction Treatment Expanded After Implementation Of The Affordable Care Act. Health Affairs, 2018, 37, 1216-1222.	2.5	42
409	Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. American Journal of Preventive Medicine, 2018, 54, S230-S242.	1.6	177
410	QT length during methadone maintenance treatment: gene-dose interaction. Fundamental and Clinical Pharmacology, 2019, 33, 96-106.	1.0	10
412	Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 2019, 140, 313-339.	2.2	39
413	A New Way Forward in the Emergency Department. Journal of Medical Toxicology, 2019, 15, 220-222.	0.8	2
414	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 2019, 106, 19-28.	1.5	21
415	Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal of Substance Abuse Treatment, 2019, 104, 34-41.	1.5	3
416	Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study. BMC Health Services Research, 2019, 19, 440.	0.9	29
417	Buprenorphine prescribing for opioid use disorder in medical practices: can office-based outpatient care address the opiate crisis in the United States?. Addiction, 2019, 114, 1992-1999.	1.7	24
418	Keeping Up with Clinical Advances: Opioid Use Disorder. CNS Spectrums, 2019, 24, 14-24.	0.7	161
419	Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?. Journal of Substance Abuse Treatment, 2019, 105, 37-43.	1.5	31
420	Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review. Systematic Reviews, 2019, 8, 186.	2.5	4
421	A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings. Journal of Substance Abuse Treatment, 2019, 104, 135-143.	1.5	14
422	Discovery of Novel Biased Opioid Receptor Ligands through Structure-Based Pharmacophore Virtual Screening and Experiment. ChemMedChem, 2019, 14, 1783-1794.	1.6	5
423	Stress, craving and mood as predictors of early dropout from opioid agonist therapy. Drug and Alcohol Dependence, 2019, 202, 200-208.	1.6	68

#	ARTICLE	IF	CITATIONS
424	Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients. <i>American Journal on Addictions</i> , 2019, 28, 409-412.	1.3	12
425	Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. <i>JAMA Network Open</i> , 2019, 2, e196373.	2.8	187
426	Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 110-116.	0.4	3
427	Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 110-116.	0.4	7
428	Characteristics and current clinical practices of opioid treatment programs in the United States. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107616.	1.6	31
429	The Effects of Opioids on HIV Neuropathogenesis. <i>Frontiers in Immunology</i> , 2019, 10, 2445.	2.2	42
430	Mobilizing Primary Care to Address the Opioid Use Disorder Treatment Gap. <i>Public Health Reports</i> , 2019, 134, 456-460.	1.3	8
431	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet</i> , 2019, 394, 1560-1579.	6.3	404
432	An integrated web application for decision support and automation of EHR workflow: a case study of current challenges to standards-based messaging and scalability from the EMBED trial. <i>JAMIA Open</i> , 2019, 2, 434-439.	1.0	12
433	Physicians' satisfaction with providing buprenorphine treatment. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 34.	1.2	9
434	Treatment of Opioid Use Disorder in Pediatric Medical Settings. <i>Current Addiction Reports</i> , 2019, 6, 374-382.	1.6	4
435	Acute poisoning related to the recreational use of prescription drugs: an observational study from Oslo, Norway. <i>BMC Emergency Medicine</i> , 2019, 19, 55.	0.7	8
436	Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting. <i>BMC Health Services Research</i> , 2019, 19, 663.	0.9	6
437	Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 2796-2803.	1.3	132
438	Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4294.	1.8	59
439	Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 30.	1.2	67
440	Outcome of Patients With High Depressive Symptoms on Admission to Methadone Maintenance Treatment. <i>Journal of Dual Diagnosis</i> , 2019, 15, 281-290.	0.7	7
441	Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. <i>Clinical Psychological Science</i> , 2019, 7, 1190-1206.	2.4	36

#	ARTICLE	IF	CITATIONS
442	Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. <i>Cmaj</i> , 2019, 191, E1049-E1056.	0.9	62
443	Current Understanding of the Neurobiology of Opioid Use Disorder: an Overview. <i>Current Behavioral Neuroscience Reports</i> , 2019, 6, 1-11.	0.6	12
444	Comparison of opioid use disorder among male veterans and non-veterans: Disorder rates, socio-demographics, comorbidities, and quality of life. <i>American Journal on Addictions</i> , 2019, 28, 92-100.	1.3	43
445	Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. <i>American Journal on Addictions</i> , 2019, 28, 55-62.	1.3	131
446	Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2019, 14, 2.	1.0	28
447	Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 1-6.	1.1	48
448	Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates. <i>American Journal on Addictions</i> , 2019, 28, 270-276.	1.3	13
449	Learning from the past, looking to the future - Is there a place for injectable opioid treatment among Australia's responses to opioid misuse?. <i>International Journal of Drug Policy</i> , 2019, 71, 164-168.	1.6	4
450	Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH). <i>Implementation Science</i> , 2019, 14, 48.	2.5	42
451	User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial. <i>BMJ Open</i> , 2019, 9, e028488.	0.8	24
452	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health</i> , The, 2019, 4, e334-e342.	4.7	29
453	A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients. <i>Drug and Alcohol Dependence</i> , 2019, 201, 127-133.	1.6	16
454	Modelling the combined impact of interventions in averting deaths during a synthetic opioid overdose epidemic. <i>Addiction</i> , 2019, 114, 1602-1613.	1.7	124
455	Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 42-50.	1.5	7
456	Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder. <i>Drugs in R and D</i> , 2019, 19, 255-265.	1.1	10
457	Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 11.	1.2	37
458	Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 20.	1.2	65
459	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. <i>International Journal of Drug Policy</i> , 2019, 72, 160-168.	1.6	23

#	ARTICLE	IF	CITATIONS
460	Buprenorphine Treatment for Opioid Use Disorder: An Overview. <i>CNS Drugs</i> , 2019, 33, 567-580.	2.7	86
461	The case for a medication first approach to the treatment of opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 333-340.	1.1	41
462	Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. <i>Harm Reduction Journal</i> , 2019, 16, 31.	1.3	21
463	Buprenorphine unobserved "home" induction: a survey of Ontario's addiction physicians. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 18.	1.2	3
464	A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: Lessons learned from the EMBED trial stakeholders. <i>Journal of Substance Abuse Treatment</i> , 2019, 102, 47-52.	1.5	25
465	Ginseng treatment improves the sexual side effects of methadone maintenance treatment. <i>Psychiatry Research</i> , 2019, 276, 142-150.	1.7	17
466	Intact responses to non-drug rewards in long-term opioid maintenance treatment. <i>Neuropsychopharmacology</i> , 2019, 44, 1456-1463.	2.8	10
467	Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine. <i>Neuropharmacology</i> , 2019, 158, 107609.	2.0	44
468	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. <i>Addiction</i> , 2019, 114, 1416-1426.	1.7	75
469	Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. <i>BMJ Open</i> , 2019, 9, e027117.	0.8	21
470	Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 377-382.	1.0	7
471	Association of current and past opioid use disorders with health-related quality of life and employment among US adults. <i>Drug and Alcohol Dependence</i> , 2019, 199, 122-128.	1.6	55
472	Is thrombotic event a side effect of oral buprenorphine abuse? Two case reports. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 740-743.	0.2	2
473	Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. <i>Substance Abuse</i> , 2019, 40, 132-135.	1.1	29
474	The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial. <i>Drug and Alcohol Dependence</i> , 2019, 197, 220-227.	1.6	16
475	Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. <i>Addiction</i> , 2019, 114, 1396-1404.	1.7	32
476	Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder. <i>International Journal of Drug Policy</i> , 2019, 67, 24-33.	1.6	30
477	Sexual Dysfunction and Quality of Life in Chronic Heroin-Dependent Individuals on Methadone Maintenance Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 321.	1.0	14

#	ARTICLE	IF	CITATIONS
478	Slow release oral morphine versus methadone for the treatment of opioid use disorder. <i>BMJ Open</i> , 2019, 9, e025799.	0.8	38
479	Opioid addiction: long-acting formulations for a long-term disorder. <i>Lancet, The</i> , 2019, 393, 723-724.	6.3	0
480	Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 272-279.	1.0	21
481	Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis. <i>American Journal of Public Health</i> , 2019, 109, 393-394.	1.5	11
482	Comparing Canadian and United States opioid agonist therapy policies. <i>International Journal of Drug Policy</i> , 2019, 74, 257-265.	1.6	50
483	Transdermal buprenorphine patch: Potential for role in management of opioid dependence. <i>Asian Journal of Psychiatry</i> , 2019, 40, 88-91.	0.9	11
484	Associations between implementation of Project Lazarus and opioid analgesic dispensing and buprenorphine utilization in North Carolina, 2009-2014. <i>Injury Epidemiology</i> , 2019, 6, 2.	0.8	5
485	Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. <i>Addictive Behaviors</i> , 2019, 93, 14-19.	1.7	16
486	Buprenorphine Overdose in Young Children: An Underappreciated Risk. <i>Clinical Pediatrics</i> , 2019, 58, 613-617.	0.4	7
487	Use of Filter Paper to Measure Alcohol Biomarkers among Opioid-Dependent Patients on Agonist Maintenance Treatment: A Community-Based Study. <i>Indian Journal of Psychological Medicine</i> , 2019, 41, 529-534.	0.6	5
488	Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series. <i>Indian Journal of Psychological Medicine</i> , 2019, 41, 586-588.	0.6	1
489	Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. <i>Cmaj</i> , 2019, 191, E462-E468.	0.9	24
490	Predictors of Medication-Assisted Treatment Initiation for Opioid Use Disorder in an Interdisciplinary Primary Care Model. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 724-731.	0.8	33
491	Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 46.	1.2	8
492	Opioid Use in Pregnancy. <i>Current Psychiatry Reports</i> , 2019, 21, 118.	2.1	34
493	Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. <i>PLoS Medicine</i> , 2019, 16, e1002963.	3.9	21
494	Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107672.	1.6	8
495	Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders. <i>JAMA Network Open</i> , 2019, 2, e1913818.	2.8	9

#	ARTICLE	IF	CITATIONS
496	Predicting Opioid Overdose Deaths Using Prescription Drug Monitoring Program Data. <i>American Journal of Preventive Medicine</i> , 2019, 57, e211-e217.	1.6	29
497	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. <i>PLoS Medicine</i> , 2019, 16, e1002973.	3.9	17
498	Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 45.	1.2	4
499	Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States. <i>Annals of Family Medicine</i> , 2019, 17, 212-220.	0.9	18
500	Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2019, 14, 50.	1.0	12
501	Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge. <i>Journal of Addiction Medicine</i> , 2019, 13, 113-118.	1.4	3
502	Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2019, 13, 354-361.	1.4	15
503	A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 888.	1.3	2
504	Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2019, 14, 57.	1.0	4
505	Initiation and Rapid Titration of Methadone in an Acute Care Setting for the Treatment of Opioid Use Disorder: A Case Report. <i>Journal of Addiction Medicine</i> , 2019, 13, 408-411.	1.4	20
506	<p>OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 361-368.	0.4	22
507	Quality of life and well-being from the perspective of patients on opioid agonist maintenance treatment: study protocol for a systematic review of qualitative research and a scoping review of measures. <i>Systematic Reviews</i> , 2019, 8, 299.	2.5	1
508	Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs. <i>Journal of Addiction Medicine</i> , 2019, 13, 28-34.	1.4	8
509	One size does not fit allâ€”evolution of opioid agonist treatments in a naturalistic setting over 23 years. <i>Addiction</i> , 2019, 114, 103-111.	1.7	29
510	Neuroimmune mechanisms of psychostimulant and opioid use disorders. <i>European Journal of Neuroscience</i> , 2019, 50, 2562-2573.	1.2	64
511	Characteristics and prescribing practices of clinicians recently waived to prescribe buprenorphine for the treatment of opioid use disorder. <i>Addiction</i> , 2019, 114, 471-482.	1.7	114
512	Initiating methadone in jail and in the community: Patient differences and implications of methadone treatment for reducing arrests. <i>Journal of Substance Abuse Treatment</i> , 2019, 97, 7-13.	1.5	7
513	Methadone maintenance treatment patients with a history of childhood trauma succeed more in a cognitive paradigm that is associated with a negative reward. <i>Psychiatry Research</i> , 2019, 271, 381-388.	1.7	7

#	ARTICLE	IF	CITATIONS
514	Historical Review: Opiate Addiction and Opioid Receptors. <i>Cell Transplantation</i> , 2019, 28, 233-238.	1.2	96
515	Prevalent Misconceptions About Opioid Use Disorders in the United States Produce Failed Policy and Public Health Responses. <i>Clinical Infectious Diseases</i> , 2019, 69, 546-551.	2.9	17
516	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019, 114, 1346-1353.	1.7	45
517	Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder. <i>Journal of the American Psychiatric Nurses Association</i> , 2019, 25, 272-279.	0.4	2
518	Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. <i>Health Affairs</i> , 2019, 38, 14-23.	2.5	126
519	The United States opioid epidemic. <i>Seminars in Perinatology</i> , 2019, 43, 123-131.	1.1	141
520	The neurobiology of addiction. <i>Annals of the New York Academy of Sciences</i> , 2019, 1451, 5-28.	1.8	107
521	Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder. <i>Pharmacogenomics Journal</i> , 2019, 19, 260-268.	0.9	17
522	Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017. <i>Journal of Substance Abuse Treatment</i> , 2019, 96, 18-22.	1.5	23
523	Change in alcohol and other drug use during five years of continuous opioid substitution treatment. <i>Drug and Alcohol Dependence</i> , 2019, 194, 438-446.	1.6	18
524	Differences in hospital length of stay between neonates exposed to buprenorphine versus methadone in utero: A retrospective chart review. <i>Paediatrics and Child Health</i> , 2019, 24, e104-e110.	0.3	8
525	A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2020, 108, 123-128.	1.5	19
526	Subcutaneous Buprenorphine for a Patient With a History of Misusing an Indwelling Catheter: A Case Report. <i>Psychosomatics</i> , 2020, 61, 284-287.	2.5	2
527	Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study. <i>Substance Use and Misuse</i> , 2020, 55, 349-357.	0.7	18
528	Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). <i>Addiction</i> , 2020, 115, 354-367.	1.7	27
529	Implementing Group Visits for Opioid Use Disorder: A Case Series. <i>Substance Abuse</i> , 2020, 41, 174-180.	1.1	8
530	Adoption of the 275-Patient Buprenorphine Treatment Waiver for Treating Opioid Use Disorder: A State-Level Longitudinal Analysis. <i>Substance Abuse</i> , 2020, 41, 259-268.	1.1	16
531	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020, 115, 239-246.	1.7	17

#	ARTICLE	IF	CITATIONS
532	Assessing the needs of front-line providers in addressing the opioid crisis in South Carolina. <i>Journal of Substance Abuse Treatment</i> , 2020, 108, 4-8.	1.5	9
533	Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 78-87.	1.1	17
534	Findings from the recovery initiation and management after overdose (RIMO) pilot study experiment. <i>Journal of Substance Abuse Treatment</i> , 2020, 108, 65-74.	1.5	14
535	Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2343-2357.	2.9	20
536	Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. <i>Neurotherapeutics</i> , 2020, 17, 55-69.	2.1	57
537	Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data. <i>PLoS ONE</i> , 2020, 15, e0227350.	1.1	5
538	Risk factors associated with persistent chronic opioid use following THA. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2020, 30, 681-688.	0.6	8
539	Client characteristics and substance use patterns in different models of methadone maintenance therapy (MMT). <i>Journal of Substance Use</i> , 2020, 25, 377-381.	0.3	5
540	Prevalence and treatment of opioid use disorders among primary care patients in six health systems. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107732.	1.6	55
541	“Now hospital leaders are paying attention”: A qualitative study of internal and external factors influencing addiction consult services. <i>Journal of Substance Abuse Treatment</i> , 2020, 110, 59-65.	1.5	32
542	Rapid Induction of Buprenorphine/Naloxone for Chronic Pain Using a Microdosing Regimen: A Case Report. <i>A&A Practice</i> , 2020, 14, 44-47.	0.2	28
543	Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2020, 14, e44-e52.	1.4	36
544	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	1.7	46
545	In-Hospital Illicit Drug Use and Patient-Directed Discharge: Barriers to Care for Patients With Injection-Related Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa074.	0.4	51
547	Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder. <i>Medical Care</i> , 2020, 58, 919-926.	1.1	9
548	The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 559-584.	1.9	3
549	Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. <i>Journal of Addiction Medicine</i> , 2020, 14, 319-325.	1.4	16
550	Age disparities in six-month treatment retention for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108130.	1.6	16

#	ARTICLE	IF	CITATIONS
551	Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual. <i>Journal of Addiction Medicine</i> , 2020, 14, 331-336.	1.4	10
552	Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. <i>Journal of Addiction Medicine</i> , 2020, 14, e233-e240.	1.4	31
553	Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs. <i>Preventive Medicine</i> , 2020, 140, 106194.	1.6	5
554	Improving translation of animal models of addiction and relapse by reverse translation. <i>Nature Reviews Neuroscience</i> , 2020, 21, 625-643.	4.9	117
555	Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs—United States, 2016—2019: Perspectives on Recent Experience and Lessons Learned. <i>Journal of Infectious Diseases</i> , 2020, 222, S239-S249.	1.9	73
556	Suicidal ideation and attempts following nonmedical use of prescription opioids and related disorder. <i>Psychological Medicine</i> , 2022, 52, 372-378.	2.7	7
557	Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone microdosing—a case series. <i>Drug and Alcohol Review</i> , 2020, 39, 588-594.	1.1	31
558	Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model. <i>Annals of Family Medicine</i> , 2020, 18, 535-544.	0.9	6
559	Maintenance agonist treatments for opiate-dependent pregnant women. <i>The Cochrane Library</i> , 2020, 2020, CD006318.	1.5	12
560	Operationalizing and selecting outcome measures for the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108328.	1.6	14
561	Retention and outcomes for clients attending a methadone clinic in a resource-constrained setting: a mixed methods prospective cohort study in Imphal, Northeast India. <i>Harm Reduction Journal</i> , 2020, 17, 68.	1.3	7
562	A Community-Based Investigation of Stigma Toward Individuals Receiving Methadone Maintenance Treatment in China: A Randomized Case Vignette Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 601266.	1.3	6
563	Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 257-263.	0.6	26
565	Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality. <i>Health Affairs</i> , 2020, 39, 1395-1404.	2.5	25
566	Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013—2017): a prospective cohort study. <i>BMC Health Services Research</i> , 2020, 20, 668.	0.9	5
567	Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience. <i>Cmaj</i> , 2020, 192, E240-E254.	0.9	63
568	Medication Treatment for Opioid use Disorder and Community Pharmacy: Expanding Care during a National Epidemic and Global Pandemic. <i>Substance Abuse</i> , 2020, 41, 269-274.	1.1	35
569	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	1.5	13

#	ARTICLE	IF	CITATIONS
570	Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. <i>Psychopharmacology</i> , 2020, 237, 3369-3381.	1.5	16
571	Management of Opioid Misuse and Opioid Use Disorders Among Youth. <i>Pediatrics</i> , 2020, 145, S153-S164.	1.0	19
572	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e036102.	0.8	17
573	Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework. <i>Milbank Quarterly</i> , 2020, 98, 700-746.	2.1	86
574	Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada. <i>Cmaj</i> , 2020, 192, E967-E972.	0.9	38
575	Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 30.	1.2	12
576	Treating Perioperative and Acute Pain in Patients on Buprenorphine: Narrative Literature Review and Practice Recommendations. <i>Journal of General Internal Medicine</i> , 2020, 35, 3635-3643.	1.3	32
577	Surgical treatment of infective endocarditis: Results in 831 patients from a single center. <i>Journal of Cardiac Surgery</i> , 2020, 35, 2725-2733.	0.3	7
578	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 761-768.	1.1	3
579	A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 69.	1.0	27
580	Primary care versus specialty care management of opioid use disorder. <i>The Cochrane Library</i> , 0, , .	1.5	0
581	A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections. <i>Journal of Infectious Diseases</i> , 2020, 222, S513-S520.	1.9	23
582	Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3661-e3669.	2.9	33
584	Buprenorphine Dosing for the Treatment of Opioid Use Disorder Through Pregnancy and Postpartum. <i>Current Treatment Options in Psychiatry</i> , 2020, 7, 375-399.	0.7	15
585	Article Commentary: Stepped Care for Opioid use Disorder Train the Trainer (SCOUTT) Initiative: Expanding Access to Medication Treatment for Opioid use Disorder within Veterans Health Administration Facilities. <i>Substance Abuse</i> , 2020, 41, 275-282.	1.1	75
586	Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial. <i>Substance Abuse: Research and Treatment</i> , 2020, 14, 117822182097092.	0.5	0
587	Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108243.	1.6	8
589	Microdosing and standard dosing take-home buprenorphine from the emergency department: A feasibility study. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1712-1722.	0.4	21

#	ARTICLE	IF	CITATIONS
590	Review article: Rapid review of the emergency department-initiated buprenorphine for opioid use disorder. <i>EMA - Emergency Medicine Australasia</i> , 2020, 32, 924-934.	0.5	4
591	Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e203132.	2.8	30
592	Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. <i>Obstetrics and Gynecology</i> , 2020, 135, 975-975.	1.2	0
593	Temporal Changes in Non-Fatal Opioid Overdose Patterns among People who use Drugs in a Canadian Setting. <i>Substance Abuse</i> , 2020, 41, 323-330.	1.1	6
594	Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine. <i>JAMA Network Open</i> , 2020, 3, e204561.	2.8	98
595	Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others. <i>Health Affairs</i> , 2020, 39, 984-992.	2.5	41
596	Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 114, 38-52.	2.9	27
597	Retention of patients in opioid substitution treatment: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0232086.	1.1	146
598	Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid. <i>Health Affairs</i> , 2020, 39, 747-755.	2.5	44
599	Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts. <i>JAMA Network Open</i> , 2020, 3, e205734.	2.8	115
600	Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?. <i>International Journal of Drug Policy</i> , 2020, 79, 102722.	1.6	65
601	Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108083.	1.6	34
602	Trends in Infective Endocarditis Hospitalizations, Characteristics, and Valve Operations in Patients With Opioid Use Disorders in the United States: 2005-2014. <i>Journal of the American Heart Association</i> , 2020, 9, e012465.	1.6	30
603	Emergency Department Clinicians' Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 261-271.	0.6	50
604	Management of dependent use of illicit opioids. <i>BMJ, The</i> , 2020, 368, m710.	3.0	4
605	Maternity Care and Buprenorphine Prescribing in New Family Physicians. <i>Annals of Family Medicine</i> , 2020, 18, 156-158.	0.9	3
606	Local health departments and the implementation of evidence-based policies to address opioid overdose mortality. <i>Substance Abuse</i> , 2020, 41, 468-474.	1.1	8
607	Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders. <i>The Cochrane Library</i> , 2020, 2, CD012254.	1.5	6

#	ARTICLE	IF	CITATIONS
608	Treating opioid use disorders in the criminal justice system with pharmacotherapy. <i>Forensic Science International: Mind and Law</i> , 2020, 1, 100009.	0.2	2
609	Nicotine and Opioids: a Call for Co-treatment as the Standard of Care. <i>Journal of Behavioral Health Services and Research</i> , 2020, 47, 601-613.	0.6	17
610	Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. <i>Addictive Behaviors</i> , 2020, 110, 106514.	1.7	5
611	Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 13.	1.2	18
612	Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians' Confidence and Readiness to Address Substance Use Disorders. <i>Community Mental Health Journal</i> , 2020, 56, 1429-1435.	1.1	5
613	Association of Medicaid Expansion With Opioid Overdose Mortality in the United States. <i>JAMA Network Open</i> , 2020, 3, e1919066.	2.8	65
614	Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 2.	1.2	33
615	The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder. <i>PLoS ONE</i> , 2020, 15, e0227298.	1.1	52
616	Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107879.	1.6	5
617	Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz539.	0.4	20
618	Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2020, 91, 105993.	0.8	8
619	Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder. <i>Academic Emergency Medicine</i> , 2020, 27, 753-763.	0.8	28
620	Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality. <i>CNS Drugs</i> , 2020, 34, 629-642.	2.7	7
621	Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. <i>Journal of Public Health</i> , 2020, 42, 848-852.	1.0	7
622	Identification and Management of Opioid Use Disorder in Primary Care: an Update. <i>Current Psychiatry Reports</i> , 2020, 22, 23.	2.1	24
623	Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 41-48.	1.5	34
624	Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. <i>BMJ</i> , The, 2020, 368, m772.	3.0	107
625	The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. <i>Addiction</i> , 2021, 116, 83-93.	1.7	31

#	ARTICLE	IF	CITATIONS
626	The changing opioid crisis: development, challenges and opportunities. <i>Molecular Psychiatry</i> , 2021, 26, 218-233.	4.1	197
627	The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108350.	1.6	206
628	Economic Evaluation in Opioid Modeling: Systematic Review. <i>Value in Health</i> , 2021, 24, 158-173.	0.1	14
629	Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum. <i>Medical Education Online</i> , 2021, 26, 1847755.	1.1	17
630	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	1.7	5
631	It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108176.	1.5	14
632	Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. <i>Journal of Substance Abuse Treatment</i> , 2021, 122, 108214.	1.5	49
633	HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment. <i>AIDS and Behavior</i> , 2021, 25, 1247-1256.	1.4	4
634	The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. <i>Current Addiction Reports</i> , 2021, 8, 100-108.	1.6	2
635	Pain Management in Former Addicts on Medication-Assisted Treatment (MAT) Program. , 2021, , 309-325.		1
636	Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review. <i>Journal of General Internal Medicine</i> , 2022, 37, 332-340.	1.3	20
637	New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 609-628.	4.2	36
638	Caring for Pregnant and Parenting Women with Opioid Use Disorder. , 2021, , 203-221.		0
639	Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France. <i>Harm Reduction Journal</i> , 2021, 18, 11.	1.3	4
640	Treatment use patterns in a large extended-treatment tobacco cessation program: predictors and cost implications. <i>Tobacco Control</i> , 2022, 31, 549-555.	1.8	7
641	Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder. <i>Pain Medicine</i> , 2021, 22, 1205-1212.	0.9	2
642	A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs. <i>Academic Emergency Medicine</i> , 2021, 28, 542-552.	0.8	15
643	Analgesic opioid use disorders in patients with chronic non-cancer pain: A holistic approach for tailored management. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 121, 160-174.	2.9	10

#	ARTICLE	IF	CITATIONS
644	Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. <i>Case Reports in Psychiatry</i> , 2021, 2021, 1-3.	0.2	2
645	Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 11.	1.2	26
646	Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. <i>Journal of Addiction Medicine</i> , 2022, 16, 10-17.	1.4	6
647	Emergency department patients with untreated opioid use disorder: A comparison of those seeking versus not seeking referral to substance use treatment. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108428.	1.6	11
648	HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2021, 8, e67-e76.	2.1	17
649	Mobile methadone dispensing in Delhi, India: implementation research. <i>Bulletin of the World Health Organization</i> , 2021, 99, 422-428.	1.5	3
650	“We’ll be Able to Take Care of Ourselves” A Qualitative Study of Client Attitudes Toward Implementing Buprenorphine Treatment at Syringe Services Programs. <i>Substance Abuse</i> , 2021, 42, 983-989.	1.1	9
651	HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges. <i>AIDS and Behavior</i> , 2021, 25, 2591-2598.	1.4	12
652	A Brief Screening Tool for Opioid Use Disorder: EMPOWER Study Expert Consensus Protocol. <i>Frontiers in Medicine</i> , 2021, 8, 591201.	1.2	4
653	African American/Black and Latino Adults with Detectable HIV Viral Load Evidence Substantial Risk for Polysubstance Substance Use and Co-occurring Problems: A Latent Class Analysis. <i>AIDS and Behavior</i> , 2021, 25, 2501-2516.	1.4	10
654	Gender Differences in Patterns and Correlates of Continued Substance Use among Patients in Methadone Maintenance Treatment. <i>Substance Use and Misuse</i> , 2021, 56, 529-538.	0.7	3
655	Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100728.	0.5	5
656	Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders. <i>Current Addiction Reports</i> , 2021, 8, 194-207.	1.6	47
657	Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development. <i>BMC Medical Ethics</i> , 2021, 22, 30.	1.0	2
658	Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1406-1413.	0.2	2
659	Opioid use disorder in pregnancy: leveraging provider perceptions to inform comprehensive treatment. <i>BMC Health Services Research</i> , 2021, 21, 215.	0.9	12
660	Within-subject evaluation of interim buprenorphine treatment during waitlist delays. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108532.	1.6	5
661	Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108534.	1.6	14

#	ARTICLE	IF	CITATIONS
662	Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies. <i>Health Affairs</i> , 2021, 40, 562-570.	2.5	21
663	Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 424.e1-424.e12.	0.7	32
664	Article Commentary: It Will End in Tiers: A Strategy to Include "Dabblers" in the Buprenorphine Workforce after the X-Waiver. <i>Substance Abuse</i> , 2021, 42, 153-157.	1.1	37
665	Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108569.	1.6	10
666	The 5 α -reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
667	Healthcare Contacts Regarding Circulatory Conditions among Swedish Patients in Opioid Substitution Treatment, with and without On-Site Primary Healthcare. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4614.	1.2	1
668	The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance. <i>Journal of Addiction Medicine</i> , 2022, 16, 183-191.	1.4	4
669	Treatment of opioid use disorder in primary care. <i>BMJ, The</i> , 2021, 373, n784.	3.0	22
670	Expanding access to nurse-managed medication for opioid use disorder. <i>Nursing Outlook</i> , 2021, 69, 848-855.	1.5	7
671	Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report. <i>Harm Reduction Journal</i> , 2021, 18, 57.	1.3	10
672	A Novel Maintenance Therapeutic for Opioid Use Disorder. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 133-145.	1.3	3
673	Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2022, 133, 108492.	1.5	21
674	Comparing Sexual Function between Opioid Dependents Consuming Methadone or Opium Tincture. <i>Iranian Journal of Psychiatry</i> , 2021, 16, 312-319.	0.4	2
675	Facilitating rapid access to addiction treatment: a randomized controlled trial. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 34.	1.2	2
676	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108292.	1.5	7
677	New Approaches in Drug Dependence: Opioids. <i>Current Addiction Reports</i> , 2021, 8, 298-305.	1.6	10
678	Opium dependence and the potential impact of changes in treatment coverage level: A dynamic modeling study. <i>Health Promotion Perspectives</i> , 2021, 11, 240-249.	0.8	0
679	Comparison of Treatments for Cocaine Use Disorder Among Adults. <i>JAMA Network Open</i> , 2021, 4, e218049.	2.8	58

#	ARTICLE	IF	CITATIONS
680	Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12462.	0.4	1
681	Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review. <i>Journal of Dual Diagnosis</i> , 2021, 17, 207-215.	0.7	0
682	Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108710.	1.6	41
683	The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2022, 74, 575-583.	2.9	7
684	Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. <i>Contemporary Clinical Trials</i> , 2021, 105, 106394.	0.8	5
685	Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108548.	1.5	4
686	Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108538.	1.5	13
687	A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 2, 100029.	0.6	14
688	Factors Associated with Recovery and Flourishing Mental Health in a National Sample of Canadians with a History of Illicit Drug Dependence. <i>International Journal of Mental Health and Addiction</i> , 2023, 21, 81-95.	4.4	1
689	A Value Framework for Transforming Behavioral Health. <i>NEJM Catalyst</i> , 2021, 2, .	0.4	1
690	Financial sustainability of payment models for office-based opioid treatment in outpatient clinics. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 45.	1.2	3
691	Social Stigma toward Persons with Opioid Use Disorder: Results from a Nationally Representative Survey of U.S. Adults. <i>Substance Use and Misuse</i> , 2021, 56, 1752-1764.	0.7	21
692	Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0255396.	1.1	35
693	Digital Capacity and Interest in mHealth Interventions Among Individuals on Opioid Agonist Maintenance Treatment: A Cross-Sectional Community-Based Study. <i>Indian Journal of Psychological Medicine</i> , 2022, 44, 354-358.	0.6	2
694	Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017–2019. <i>Harm Reduction Journal</i> , 2021, 18, 93.	1.3	12
695	Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108342.	1.5	16
696	Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	8
697	Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. <i>Regional Anesthesia and Pain Medicine</i> , 2021, 46, 840-859.	1.1	51

#	ARTICLE	IF	CITATIONS
698	A Comparative Analysis of Online Versus in-Person Opioid Overdose Awareness and Reversal Training for First-Year Medical Students. <i>Substance Use and Misuse</i> , 2021, 56, 1962-1971.	0.7	13
699	Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder. <i>JAMA Network Open</i> , 2021, 4, e2118487.	2.8	22
700	Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108399.	1.5	31
701	Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108786.	1.6	10
702	Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. <i>Systematic Reviews</i> , 2021, 10, 216.	2.5	31
703	An Effective and Safe Novel Treatment of Opioid Use Disorder: Unilateral Transcranial Photobiomodulation. <i>Frontiers in Psychiatry</i> , 2021, 12, 713686.	1.3	5
704	Methadone Contrasted with Acetaminophen Codeine plus Clonidine: An Inpatient Pilot Study. <i>Current Psychopharmacology</i> , 2021, 10, .	0.1	0
705	Cannabis use is associated with lower retention in methadone maintenance treatment, but not among schizophrenic- and other chronically psychotic patients. <i>Journal of Addictive Diseases</i> , 2021, , 1-9.	0.8	0
706	Contingency Management for Patients Receiving Medication for Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 1092.	6.0	64
707	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , 2022, 117, 637-645.	1.7	4
708	Recent advances in the treatment of opioid use disorders—focus on long-acting buprenorphine formulations. <i>World Journal of Psychiatry</i> , 2021, 11, 543-552.	1.3	3
709	An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108886.	1.6	8
710	Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder?. <i>Journal of Medical Toxicology</i> , 2022, 18, 11-18.	0.8	6
711	Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations. <i>Drugs and Aging</i> , 2021, 38, 1043-1053.	1.3	29
712	Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. <i>AIDS and Behavior</i> , 2022, 26, 975-985.	1.4	8
713	Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont. <i>Preventive Medicine</i> , 2021, 152, 106817.	1.6	4
714	Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. <i>Substance Use and Misuse</i> , 2021, 56, 2181-2201.	0.7	58
715	Barriers and facilitators associated with establishment of emergency department-initiated buprenorphine for opioid use disorder in rural Maine. <i>Journal of Rural Health</i> , 2021, , .	1.6	1

#	ARTICLE	IF	CITATIONS
716	Analysis of genetic and clinical factors associated with buprenorphine response. <i>Drug and Alcohol Dependence</i> , 2021, 227, 109013.	1.6	2
717	Video directly observed therapy for patients receiving office-based buprenorphine – A pilot randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108917.	1.6	10
718	Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014–2018. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108937.	1.6	10
719	A feasibility study of a peer-facilitated physical activity intervention in methadone maintenance. <i>Mental Health and Physical Activity</i> , 2021, 21, 100419.	0.9	12
720	“You get that craving and you go for a half-hour run” Exploring the acceptability of exercise as an adjunct treatment for substance use disorder. <i>Mental Health and Physical Activity</i> , 2021, 21, 100424.	0.9	4
721	Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. <i>Drug and Alcohol Dependence</i> , 2021, 228, 108923.	1.6	17
722	Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108415.	1.5	9
723	Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109006.	1.6	2
724	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108447.	1.5	12
725	Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. <i>International Journal of Drug Policy</i> , 2021, 98, 103400.	1.6	10
726	Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108452.	1.5	10
727	Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States. <i>Addictive Behaviors</i> , 2022, 124, 107113.	1.7	15
728	Successful Transition from High-Dose Methadone to Buprenorphine via Microdosing in the Outpatient Setting: A Case Report. <i>Canadian Journal of Hospital Pharmacy</i> , 2021, 74, .	0.1	4
729	A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse. <i>Psychopharmacology</i> , 2021, 238, 1029-1046.	1.5	30
730	“It’s way more than just writing a prescription” A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 8.	1.2	13
733	Enhancing Treatment Access and Effectiveness: Toward Patient-Centered Models of Care. <i>Current Clinical Psychiatry</i> , 2019, , 197-222.	0.2	1
734	Psychosocial Approaches in the Treatment of Opioid Use Disorders. <i>Current Clinical Psychiatry</i> , 2019, , 109-138.	0.2	4
735	Women and Pregnancy. , 2020, , 259-275.		2

#	ARTICLE	IF	CITATIONS
736	Opioids: clinical use. , 2006, , 443-457.		24
737	Psychological Treatments of Substance Misuse and Dependence. , 2007, , 209-239.		2
738	Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties. Addictive Behaviors, 2019, 93, 72-77.	1.7	14
739	Increased DNA Methylation of ABCB1 , CYP2D6 , and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers. Journal of Pediatrics, 2017, 190, 180-184.e1.	0.9	35
740	Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal of Substance Abuse Treatment, 2019, 100, 18-28.	1.5	39
741	Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. Journal of Substance Abuse Treatment, 2020, 111, 54-66.	1.5	28
744	Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.. Experimental and Clinical Psychopharmacology, 2018, 26, 403-409.	1.3	20
745	Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.. Experimental and Clinical Psychopharmacology, 2018, 26, 570-581.	1.3	10
746	Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.. Experimental and Clinical Psychopharmacology, 2020, 28, 449-461.	1.3	20
747	Substance use in rural Central Appalachia: Current status and treatment considerations.. Journal of Rural Mental Health, 2017, 41, 123-135.	0.5	101
748	Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs. Journal of Addiction Medicine, 2020, 14, 282-286.	1.4	22
749	Medications Development for Treatment of Opioid Use Disorder. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a039263.	2.9	13
750	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. Journal of General Internal Medicine, 2006, 21, 193-5.	1.3	66
751	Is methadone too dangerous for opiate addiction?: Issue is one of toxicity v acceptability. BMJ: British Medical Journal, 2006, 332, 53.1.	2.4	3
752	Is methadone too dangerous for opiate addiction?: Methadone is still needed in addiction treatments. BMJ: British Medical Journal, 2006, 332, 53.2.	2.4	2
753	The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open, 2015, 5, e007629.	0.8	42
754	Medications for opioid use disorders: clinical and pharmacological considerations. Journal of Clinical Investigation, 2019, 130, 10-13.	3.9	25
755	Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder. Substance Abuse: Research and Treatment, 2020, 14, 117822182098199.	0.5	4

#	ARTICLE	IF	CITATIONS
756	Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment. PLoS ONE, 2015, 10, e0130050.	1.1	59
757	Methodological quality of systematic reviews referenced in clinical practice guidelines for the treatment of opioid use disorder. PLoS ONE, 2017, 12, e0181927.	1.1	18
758	Bacterial and Fungal Infections in Persons Who Inject Drugs â€” Western New York, 2017. Morbidity and Mortality Weekly Report, 2019, 68, 583-586.	9.0	34
759	Substance Use Disorders in the U.S. Armed Forces. , 2013, , .		20
760	Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers. Journal of Addiction Medicine and Therapeutic Science, 2015, 1, 031-036.	0.3	35
761	Opioid treatment of opioid addiction. Australian Prescriber, 2013, 36, 83-87.	0.5	5
762	Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis. Current HIV Research, 2016, 14, 417-430.	0.2	11
763	Substance Use in Adolescents Presenting to the Emergency Department. Adolescent Psychiatry (Hilversum, Netherlands), 2020, 9, 142-158.	0.1	4
764	Computerized Clinical Decision Support System for Emergency Departmentâ€”Initiated Buprenorphine for Opioid Use Disorder: User-Centered Design. JMIR Human Factors, 2019, 6, e13121.	1.0	22
765	Identifying Opioid Use Disorder in the Emergency Department: Multi-System Electronic Health Recordâ€”Based Computable Phenotype Derivation and Validation Study. JMIR Medical Informatics, 2019, 7, e15794.	1.3	20
766	Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural and Remote Health, 0, , .	0.4	73
767	Dismantling Buprenorphine Policy Can Provide More Comprehensive Addiction Treatment. NAM Perspectives, 2019, 2019, .	1.3	5
768	Treatment of opioid dependence with buprenorphine: current update. Dialogues in Clinical Neuroscience, 2017, 19, 299-308.	1.8	14
769	Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment, 2007, 11, 1-171, iii-iv.	1.3	390
770	Long-term Consequences of Acute Pain for Patients under Methadone or Buprenorphine Maintenance Treatment. Pain Physician, 2013, 6;16, E739-E747.	0.3	11
771	Harm-Reduction Strategies for Injection Drug Use. Psychiatric Annals, 2017, 47, 45-48.	0.1	2
772	Managing Opioid Abuse in Older Adults: Clinical Considerations and Challenges. Journal of Gerontological Nursing, 2016, 42, 10-15.	0.3	9
773	Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study. Indian Journal of Psychological Medicine, 2015, 37, 330-332.	0.6	12

#	ARTICLE	IF	CITATIONS
774	Sexual dysfunction in men on buprenorphine + naloxone-based substitution therapy. Indian Journal of Psychiatry, 2020, 62, 66.	0.4	10
775	Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions. Indian Journal of Psychiatry, 2018, 60, 361.	0.4	8
776	The journey of opioid substitution therapy in India: Achievements and challenges. Indian Journal of Psychiatry, 2017, 59, 39.	0.4	33
777	A Comparison of Suboxone and Methadone in the Treatment of Opiate Addiction. Journal of Addiction Research & Therapy, 2015, 06, .	0.2	5
778	Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings. The Journal of Addictive Behaviors & Rehabilitation, 2015, 04, .	0.2	23
779	A claims analysis of the utilization of tramadol for acute pain in patients prescribed buprenorphine/naloxone for opioid use disorder. Journal of Opioid Management, 2018, 14, 407-413.	0.2	1
780	The influence of programme differences on crime reduction in opioid maintenance treatment. An analysis of regional patterns in Norway. Norsk Epidemiologi, 2011, 21, .	0.2	2
781	Canadian Guidelines on Opioid Use Disorder Among Older Adults. Canadian Geriatrics Journal, 2020, 23, 123-134.	0.7	20
782	Dynamic changes in prescription opioids from 2006 to 2017 in Texas. PeerJ, 2019, 7, e8108.	0.9	12
783	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. Substance Abuse, 2021, 42, 245-254.	1.1	22
785	Is extended release naltrexone superior to buprenorphine + naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 2021, 45, 2569-2578.	1.4	3
786	Experiences with an Addiction Consultation Service on Care Provided to Hospitalized Patients with Opioid use Disorder: A Qualitative Study of Hospitalists, Nurses, Pharmacists, and Social Workers. Substance Abuse, 2022, 43, 615-622.	1.1	9
787	Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug and Alcohol Review, 2022, 41, 444-448.	1.1	17
789	Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. Journal of Substance Abuse Treatment, 2022, 133, 108647.	1.5	13
790	Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment. Journal of Substance Abuse Treatment, 2022, 135, 108644.	1.5	6
792	Maintenance Therapy and Sexual Behavior. , 0, , .		0
793	Sexual Dysfunctions - Special Issues. , 2011, , .		0
794	Headache in Buprenorphine Detoxification Treatment. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	0

#	ARTICLE	IF	CITATIONS
796	Buprenorphine for opioid dependence. <i>Mental Health Clinician</i> , 2013, 3, 286-289.	0.5	1
797	Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study. <i>Swiss Medical Weekly</i> , 2014, 144, w13933.	0.8	10
798	Cost Effectiveness of Harm Reduction: Comparison Needle and Syringe Exchange Programme. <i>Singaporean Journal of Business Economics and Management Studies</i> , 2015, 3, 207-211.	0.1	0
799	Care of the Patient Who Misuses Drugs. , 2015, , 1-14.		0
800	Suchterkrankungen. , 2015, , 291-347.		1
802	Detecting Anomalies in Controlled Drug Prescription Data Using Probabilistic Models. <i>Lecture Notes in Computer Science</i> , 2015, , 337-349.	1.0	4
803	Buprenorphine-Naloxone Treatment of Prescription Opioid Abuse: Does Past Performance Predict Future Results?. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 195-197.	1.1	0
804	What are the benefits and harms of buprenorphine maintenance versus placebo or methadone maintenance in people with opioid dependence?. <i>Cochrane Clinical Answers</i> , 0, , .	0.0	0
805	The Effectiveness of Method on Maintenance Treatment on the Addicted Life Quality in the World: Meta " Analysis and Systematic Review. <i>International Journal of Virology Studies & Research</i> , 0, , 34-41.	0.0	0
807	Hospitalist Management of Injectable Drugs of Abuse. , 2018, , 243-255.		0
809	Pilot Study of Problem Gambling in Specialized Substance Use Disorder Treatment"High Lifetime Prevalence of Problem Gambling in Opioid Maintenance Treatment Patients. <i>Open Journal of Psychiatry</i> , 2018, 08, 233-243.	0.2	1
812	Therapeutic Communities and the Judicial System in the United States. , 2019, , 113-132.		1
817	The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations" Cmaj, 2019, 191, E1085-E1085.	0.9	1
819	Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder. <i>Journal of Psychiatry and Brain Science</i> , 2020, 5, .	0.3	10
822	Buprenorphine implants: review of literature evidence and impacts on subjects with opioid use disorders. <i>Minerva Psichiatrica: A Journal on Psychiatry, Psychology and Psychopharmacology</i> , 2020, 61, .	0.6	0
823	The opioid epidemic and endocarditis: Frontiers in the management of injection drug use"related endocarditis. <i>JTCVS Open</i> , 2021, 8, 315-320.	0.2	2
824	Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder. <i>Trials</i> , 2021, 22, 757.	0.7	4
825	Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study. <i>European Addiction Research</i> , 2022, 28, 143-154.	1.3	4

#	ARTICLE	IF	CITATIONS
826	The impact of lofexidine on stress-related opioid craving and relapse: Design and methodology of a randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2021, 111, 106616.	0.8	0
827	Therapeutic management of substance use disorders (II). <i>Psihiatru Ro</i> , 2020, 1, 14.	0.0	0
828	An Open-label Randomized Control Trial Comparing Clonidine and Buprenorphine for Medically-Assisted Opium Withdrawal of Adolescents. <i>International Journal of High Risk Behaviors & Addiction</i> , 2020, 9, .	0.1	0
829	Initiation of Buprenorphine/Naloxone on Rates of Discharge Against Medical Advice. <i>Hospital Pharmacy</i> , 2022, 57, 88-92.	0.4	4
830	Recent Advances in the Treatment of Opioid Use Disorders. <i>Techniques in Neurosurgery & Neurology</i> , 2020, 3, .	0.0	2
831	Long-term treatment outcomes in a First Nations high school population with opioid use disorder. <i>Canadian Family Physician</i> , 2020, 66, 907-912.	0.1	1
833	Unravelling the "Black Box": Treatment-Staff Perceptions of Hermon Prison's Drug-Rehabilitation Program. <i>International Journal of Criminology and Sociology (discontinued)</i> , 0, 9, 124-134.	2.0	0
834	Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report. <i>Mental Health Clinician</i> , 2021, 11, 369-372.	0.5	3
835	Epidemic Meets Pandemic:. <i>Delaware Journal of Public Health</i> , 2020, 6, 42-43.	0.2	0
837	Cocaine Addiction and Treatment. , 2021, , 173-186.		0
838	Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. <i>Rhode Island Medical Journal (2013)</i> , 2014, 97, 20-4.	0.2	4
840	Opioid agonist therapy. <i>Canadian Family Physician</i> , 2017, 63, 509-510.	0.1	4
841	The placebo effect in psychiatric practice. <i>Current Psychiatry</i> , 2017, 16, 29-34.	1.7	3
842	The Opioid Crisis in Missouri: A Call to Action for Physicians, Legislators, and Society. <i>Missouri Medicine</i> , 2017, 114, 440-446.	0.3	5
843	Quality of primary care among individuals receiving treatment for opioid use disorder. <i>Canadian Family Physician</i> , 2019, 65, 343-351.	0.1	18
844	Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes. <i>Canadian Family Physician</i> , 2019, 65, e443-e452.	0.1	1
845	Medications for Opioid Use Disorder: A Guide for Physicians. <i>Missouri Medicine</i> , 2020, 117, 59-64.	0.3	3
846	Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 137.	0.9	0

#	ARTICLE	IF	CITATIONS
847	Successful Transition from High-Dose Methadone to Buprenorphine via Microdosing in the Outpatient Setting: A Case Report. <i>Canadian Journal of Hospital Pharmacy</i> , 2021, 74, 83-85.	0.1	4
848	Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam. <i>International Journal of Drug Policy</i> , 2022, 100, 103503.	1.6	0
849	The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial. <i>Journal of Substance Abuse Treatment</i> , 2022, 136, 108666.	1.5	4
850	Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 718811.	1.6	7
851	Substance Use, Hospitalizations, and Co-Occurring Disorders among Patients Transferred from a Needle Exchange Program to Opioid Maintenance Treatment. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 697.	1.2	2
852	Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014–2020. <i>International Journal of Drug Policy</i> , 2022, 101, 103545.	1.6	1
853	Buprenorphine differentially alters breathing among four congenic mouse lines as a function of dose, sex, and leptin status. <i>Respiratory Physiology and Neurobiology</i> , 2022, 297, 103834.	0.7	2
854	A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2022, , 108722.	1.5	3
855	Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 804997.	1.3	3
856	A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone. <i>Indian Journal of Psychological Medicine</i> , 0, , 025371762110667.	0.6	1
857	Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2022, 175, ITC1-ITC16.	2.0	16
858	Interim opioid agonist treatment for opioid addiction: a systematic review. <i>Harm Reduction Journal</i> , 2022, 19, 7.	1.3	4
860	Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily. <i>AIDS and Behavior</i> , 2022, , 1.	1.4	1
861	“In their mind, they always felt less than” The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention. <i>Journal of Substance Abuse Treatment</i> , 2022, 138, 108721.	1.5	18
862	The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. <i>Substance Abuse and Rehabilitation</i> , 2022, Volume 13, 1-12.	1.6	51
863	Latent COVID-19 Clusters in Patients with Opioid Misuse. <i>Studies in Health Technology and Informatics</i> , 2022, 289, 123-127.	0.2	0
864	Perioperative Opioids, the Opioid Crisis, and the Anesthesiologist. <i>Anesthesiology</i> , 2022, 136, 594-608.	1.3	26
865	A transition of power in opioid substitution treatment: Clinic managers' views on the consequences of a patient choice reform. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 0, , 145507252210750.	0.7	2

#	ARTICLE	IF	CITATIONS
866	Nonparametric causal mediation analysis for stochastic interventional (in)direct effects. <i>Biostatistics</i> , 2023, 24, 686-707.	0.9	3
867	The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109336.	1.6	6
868	Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India. <i>Journal of Neurosciences in Rural Practice</i> , 0, 13, 176-180.	0.3	0
869	Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service. , 2022, 2, 100031.		3
870	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	1.1	7
871	Healthcare seeking among Swedish patients in opioid substitution treatment – a mixed methods study on barriers and facilitators. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, 8.	1.0	3
873	Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence. <i>Indian Journal of Psychiatry</i> , 2022, 64, 199.	0.4	6
874	Comparative Analysis of Patient Distress in Opioid Treatment Programs using Natural Language Processing. , 2022, 2022, 319-326.		0
875	Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy. <i>Pharmaceutics</i> , 2022, 14, 461.	2.0	2
876	Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: “Ultrarapid Micro-Dosing” Proof of Concept. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 94-101.	1.0	3
877	Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic. <i>Journal of Substance Abuse Treatment</i> , 2022, 139, 108777.	1.5	11
878	Patterns of and Rationale for the Co-use of Methamphetamine and Opioids: Findings From Qualitative Interviews in New Mexico and Nevada. <i>Frontiers in Psychiatry</i> , 2022, 13, 824940.	1.3	7
879	Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway. <i>BMC Psychiatry</i> , 2022, 22, 181.	1.1	4
881	Continuing Increase in Stimulant Dependence – Time to Implement Medical Treatment. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 507-511.	0.9	4
882	Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2022, 17, e0266142.	1.1	13
883	Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 15.	1.2	15
884	Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study. <i>JMIR Formative Research</i> , 2022, 6, e33073.	0.7	11
885	Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. <i>JAMA Network Open</i> , 2022, 5, e223821.	2.8	78

#	ARTICLE	IF	CITATIONS
886	Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. <i>Journal of Substance Abuse Treatment</i> , 2022, 139, 108774.	1.5	4
887	Mobile Narcotic Treatment Programs: On the Road Again?. <i>Cureus</i> , 2022, 14, e23221.	0.2	5
888	Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 16.	1.2	7
889	Characteristics of and Experience Among People Who Use Take-Home Naloxone in SkÅ¥ne County, Sweden. <i>Frontiers in Public Health</i> , 2022, 10, 811001.	1.3	5
890	Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. <i>Annals of Emergency Medicine</i> , 2022, 79, 441-450.	0.3	8
891	Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2022, 3, e220093.	1.0	17
892	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	1.7	3
893	Contribution of pharmaceutical drugs of dependence to the incidence of neonatal abstinence syndrome in Western Australia between 2003 and 2018. <i>Pharmacotherapy</i> , 2022, 42, 405-410.	1.2	4
894	Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. <i>American Journal on Addictions</i> , 2022, 31, 256-260.	1.3	3
895	Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109389.	1.6	4
896	Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data. , 2022, 3, 100048.		0
897	The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice. <i>Substance Use and Misuse</i> , 2022, 57, 308-315.	0.7	0
898	Acupuncture for Opioid Dependence Patients Receiving Methadone Maintenance Treatment: A Network Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 767613.	1.3	3
899	Redesign of Opioid Use Disorder Screening and Treatment in the ED. <i>NEJM Catalyst</i> , 2021, 3, .	0.4	2
900	The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108714.	1.5	1
901	Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. <i>JAMA Network Open</i> , 2022, 5, e227028.	2.8	22
902	The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 48.	0.6	2
903	The Prevalence and Psychosocial Correlates of Ketum (<i>Mitragyna speciosa</i>) Use among Individuals on Methadone Maintenance Therapy Programme in Hospital Taiping, Malaysia. <i>Healthcare (Switzerland)</i> , 2022, 10, 746.	1.0	2

#	ARTICLE	IF	CITATIONS
904	Patient-centered addiction medicine: What patients say helps them the most in their recovery - the role of whole-person Healthcare and prayer in opioid addiction recovery. <i>Current Psychology</i> , 0, , 1.	1.7	0
905	A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD). <i>Journal of Medical Toxicology</i> , 2022, , 1.	0.8	0
906	Sociodemographic Differences in Quality of Treatment to Medicaid Enrollees Receiving Buprenorphine. <i>Substance Abuse</i> , 2022, 43, 1057-1071.	1.1	7
907	A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova. <i>International Journal of Drug Policy</i> , 2022, 104, 103683.	1.6	5
910	Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	1.1	4
912	Assessing Opioid Use Disorder Treatments in Trials Subject to Non-Adherence via a Functional Generalized Linear Mixed-Effects Model. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5456.	1.2	0
913	Management of Postoperative Pain in Patients Following Spine Surgery: A Narrative Review. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4535-4549.	0.8	14
914	Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100918.	0.5	2
915	Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey. <i>Social Science and Medicine</i> , 2022, 305, 115034.	1.8	5
916	Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability. , 2022, 3, 100067.		5
917	Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study. <i>Western Journal of Emergency Medicine</i> , 2022, 23, 386-395.	0.6	3
918	Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. <i>CNS Drugs</i> , 2022, 36, 617-632.	2.7	8
919	Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, .	1.0	14
920	Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment. <i>Journal of Personalized Medicine</i> , 2022, 12, 835.	1.1	0
921	Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 481-491.	1.1	4
922	Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. <i>Addiction</i> , 2022, 117, 2662-2672.	1.7	6
923	Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs. <i>JAMA Health Forum</i> , 2022, 3, e221757.	1.0	12
924	Models for Implementing Emergency Department-Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers. <i>Annals of Emergency Medicine</i> , 2022, 80, 410-419.	0.3	8

#	ARTICLE	IF	CITATIONS
925	Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2022, , 108824.	1.5	0
926	Expanding access to medications for opioid use disorder through locally-initiated implementation. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	1.2	7
927	Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor. <i>MedComm</i> , 2022, 3, .	3.1	5
928	Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study. <i>PLoS ONE</i> , 2022, 17, e0269379.	1.1	1
929	Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis. <i>Science Advances</i> , 2022, 8, .	4.7	20
930	Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study. <i>International Journal of Drug Policy</i> , 2022, 106, 103768.	1.6	10
931	“You’re Not Supposed to be on it Forever” Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182211038.	0.5	16
932	Scope of, Motivations for, And Outcomes of Diverted Buprenorphine Among People Using Buprenorphine: A Scoping Review. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
933	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
934	Resident attitudes, experiences, and preferences on initiating buprenorphine in the emergency department: A national survey. <i>AEM Education and Training</i> , 2022, 6, .	0.6	3
935	User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial. <i>BMJ</i> , The, 0, , e069271.	3.0	11
936	Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials. <i>BMC Medicine</i> , 2022, 20, .	2.3	10
937	Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 1307.	1.0	1
938	Feasibility, Acceptability, and Preliminary Efficacy of a Smartphone-Based Contingency Management Intervention for Buprenorphine Adherence. <i>Behavior Analysis in Practice</i> , 0, , .	1.5	3
939	Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. <i>Hospital Practice (1995)</i> , 2022, 50, 251-258.	0.5	0
940	The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. <i>Addiction</i> , 2023, 118, 97-107.	1.7	7
941	Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	6
942	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. <i>International Journal of Drug Policy</i> , 2022, 107, 103788.	1.6	18

#	ARTICLE	IF	CITATIONS
944	Altered Accumbal Dopamine Terminal Dynamics Following Chronic Heroin Self-Administration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8106.	1.8	4
945	The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, .	1.0	3
946	Patientsâ€™ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	1.2	1
947	Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. <i>Journal of Hospital Medicine</i> , 2022, 17, 679-692.	0.7	7
948	Healthcare utilization for somatic conditions among Swedish patients in opioid substitution treatment, with and without on-site primary healthcare. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	2
949	Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats. <i>Neuropsychopharmacology</i> , 0, , .	2.8	5
950	Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	5
951	Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2022, 5, e2223708.	2.8	12
952	Comparison of psychiatric disorders in addicted patients treated with buprenorphine, methadone, and opium tincture in Iran. <i>Middle East Current Psychiatry</i> , 2022, 29, .	0.5	1
954	Improving Management of Opioid Use Disorder Training With Novel Resident Co-PCP Model. <i>PRIMER (Leawood, Kan)</i> , 0, 6, .	0.6	0
955	The measurement-based care to opioid treatment programs project (MBC2OTP): a study protocol using rapid assessment procedure informed clinical ethnography. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	1.2	3
956	The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10382.	1.2	1
957	A Call to Action: Integration of Buprenorphine Prescribing Into the Care of Persons With Human Immunodeficiency Virus and Opioid Use Disorder. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
958	Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone. <i>Trials</i> , 2022, 23, .	0.7	3
959	Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. <i>Substance Use and Misuse</i> , 2022, 57, 1732-1742.	0.7	3
960	Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. <i>International Journal of Drug Policy</i> , 2022, 110, 103803.	1.6	12
961	Buprenorphine and its formulations: a comprehensive review. <i>Health Psychology Research</i> , 2022, 10, .	0.6	11
962	Anterior cingulate cortex and its projections to the ventral tegmental area regulate opioid withdrawal, the formation of opioid context associations and context-induced drug seeking. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	3

#	ARTICLE	IF	CITATIONS
963	Under-representation of key demographic groups in opioid use disorder trials. , 2022, 4, 100084.		3
964	Use of long-acting injectable buprenorphine in the correctional setting. Journal of Substance Abuse Treatment, 2022, 142, 108851.	1.5	3
965	Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence, 2022, 239, 109609.	1.6	3
966	Variation in intervention stigma among medications for opioid use disorder. SSM Qualitative Research in Health, 2022, 2, 100161.	0.6	4
967	Medication-Assisted Treatment (MAT) 1: Opioid Substitution Therapy. , 2022, , 315-342.		0
968	NEUROSCIENTIFIC BASIS OF TREATMENT FOR SUBSTANCE USE DISORDERS. Noropsikiyatri Arsivi, 2022, , .	0.2	0
969	Stage-of-change Assessment Predicts Short-term Treatment Engagement for Opioid Use Disorder Patients Initiated on Buprenorphine. Western Journal of Emergency Medicine, 2022, 23, 684-692.	0.6	0
970	Using Natural Language Processing of Clinical Notes to Predict Outcomes of Opioid Treatment Program. , 2022, , .		2
972	Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study. , 2022, 1, 157-163.		6
973	Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder. JAMA Health Forum, 2022, 3, e223285.	1.0	2
974	Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. Addiction Science & Clinical Practice, 2022, 17, .	1.2	3
975	Mustâ€access prescription drug monitoring programs and retail opioid sales. Contemporary Economic Policy, 0, , .	0.8	1
976	Opioid agonist treatment for people who are dependent on pharmaceutical opioids. The Cochrane Library, 2022, 2022, .	1.5	6
977	Buprenorphine reverses neurocognitive impairment in EcoHIV infected mice: A potential therapy for HIV-NCI. Frontiers in Immunology, 0, 13, .	2.2	7
978	Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats. Frontiers in Psychiatry, 0, 13, .	1.3	1
979	Adapting low-dose buprenorphine induction to meet patient needs: A pilot study. , 2022, 5, 100104.		1
980	Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder. American Journal of Psychiatry, 2022, 179, 699-701.	4.0	2
981	Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research, 2022, Vol. 10, .	0.6	4

#	ARTICLE	IF	CITATIONS
982	Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study. <i>International Journal of Drug Policy</i> , 2022, 109, 103853.	1.6	4
983	Buprenorphine, Polydrug Use, and Deaths. , 2022, , 2863-2882.		0
984	Keeping it in the family. <i>American Ethnologist</i> , 0, , .	1.0	0
985	Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, .	1.0	2
986	Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	1
987	Nurse Practitionerâ€œLed Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2022, 11, e42585.	0.5	1
988	CDC Clinical Practice Guideline for Prescribing Opioids for Painâ€œ” United States, 2022. <i>MMWR Recommendations and Reports</i> , 2022, 71, 1-95.	26.7	385
989	Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder. , 2022, 5, 100106.		2
990	Effect of human mesenchymal stem cell secretome administration on morphine self-administration and relapse in two animal models of opioid dependence. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	3
991	Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	0
992	Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1
993	The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of pandemic crises impact on medication management and administration for patients with opioid use disorders. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 0, , 145507252211355.	0.7	1
994	Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability. <i>Drug and Alcohol Dependence</i> , 2022, 241, 109696.	1.6	0
995	Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2022, 17, .	1.0	6
996	Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	1.2	0
997	Gaps in Evidence-based Treatment of Concurrent Attention Deficit Hyperactivity Disorder and Opioid Use Disorder: A Scoping Review. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211410.	0.9	1
998	Examination of the nutritional intake of patients undergoing opioid replacement therapy: A systematic review. <i>Nutrition and Dietetics</i> , 2023, 80, 55-64.	0.9	3
999	Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study. <i>Patient Preference and Adherence</i> , 0, Volume 16, 3405-3413.	0.8	4

#	ARTICLE	IF	CITATIONS
1000	Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2023, 18, .	1.0	3
1001	Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study. <i>American Journal of Emergency Medicine</i> , 2023, 66, 53-60.	0.7	2
1002	Geographic variation in availability of opioid treatment programs across U.S. communities. <i>Journal of Addictive Diseases</i> , 2024, 42, 136-146.	0.8	2
1003	Measuring the preferences of injectable opioid agonist treatment (IOAT) clients: Development of a person-centered scale (best-worst scaling). <i>International Journal of Drug Policy</i> , 2023, 112, 103948.	1.6	3
1004	Principal component regression analysis of familial psychiatric histories and suicide risk factors among adults with opioid use disorder. <i>Journal of Psychiatric Research</i> , 2023, 159, 6-13.	1.5	2
1005	Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder. <i>Addictive Behaviors</i> , 2023, 140, 107604.	1.7	1
1006	Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2023, 6, e2251856.	2.8	11
1007	Buprenorphine Dispensing Among Youth Aged ≥19 Years in the United States: 2015–2020. <i>Pediatrics</i> , 2023, 151, .	1.0	1
1008	Changes and trends in medication-assisted treatment in Israel. <i>Israel Journal of Health Policy Research</i> , 2023, 12, .	1.4	3
1009	Analysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis. <i>Molecules</i> , 2023, 28, 2010.	1.7	0
1010	“Sometimes you have to take the person and show them how” adapting behavioral activation for peer recovery specialist-delivery to improve methadone treatment retention. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2023, 18, .	1.0	5
1011	Changes in daily dose in open-label compared to double-blind: The role of clients’™ expectations in injectable opioid agonist treatment. <i>Addictive Behaviors Reports</i> , 2023, 17, 100490.	1.0	0
1012	Substance Use Disorder. , 2022, , 137-155.		0
1013	Opioid Use Disorders in Organ Transplantation. , 2022, , 153-159.		0
1014	Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico. <i>Addiction Science & Clinical Practice</i> , 2023, 18, .	1.2	1
1015	Examination of methadone involved overdoses during the COVID-19 pandemic. <i>Forensic Science International</i> , 2023, 344, 111579.	1.3	5
1017	Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment. <i>Journal of Addiction Medicine</i> , 2023, 17, 215-218.	1.4	2
1018	Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’™ Perceptions and Attitudes. <i>Substance Use and Misuse</i> , 2023, 58, 512-519.	0.7	2

#	ARTICLE	IF	CITATIONS
1019	Tailoring dissemination strategies to increase evidence-informed policymaking for opioid use disorder treatment: study protocol. <i>Implementation Science Communications</i> , 2023, 4, .	0.8	6
1020	Enhancing distress tolerance to uplift motivation in recovery: Results from an open development trial. <i>Digital Health</i> , 2023, 9, 205520762311585.	0.9	0
1021	The Role of Physical Exercise in Opioid Substitution Therapy: Mechanisms of Sequential Effects. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4763.	1.8	3
1022	Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4566.	1.2	0
1023	Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists. <i>Pharmacy (Basel, Switzerland)</i> , 2023, 11, 52.	0.6	1
1024	A Case Series of Spouses Undergoing Rapid Micro Induction Technique of Buprenorphine Initiation from Methadone. <i>Kansas Journal of Medicine</i> , 2023, 16, 74-78.	0.1	0
1025	Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study. <i>BMJ Open</i> , 2023, 13, e069857.	0.8	3
1026	Variation in adverse drug events of opioids in the United States. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1027	Anesthetic Concerns in Psychiatric Disease. , 0, , .		0
1028	Incidence of Precipitated Withdrawal During a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. <i>JAMA Network Open</i> , 2023, 6, e236108.	2.8	11
1029	Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	2
1030	Rationale, evidence, and steps for implementation of medication for opioid use disorder treatment programs in HIV primary care settings. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 0, , 1-8.	0.6	0
1031	Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder. <i>JAMA Network Open</i> , 2023, 6, e237099.	2.8	1
1032	Malmö Treatment Referral and Intervention Study (MATRIS) 36-month follow-up on retention and substance use among patients referred from needle exchange to opioid agonist treatment The role of stimulant use at baseline. , 2023, , 209036.		0
1033	Implementation strategies to address the determinants of adoption, implementation, and maintenance of a clinical decision support tool for emergency department buprenorphine initiation: a qualitative study. <i>Implementation Science Communications</i> , 2023, 4, .	0.8	1
1034	The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients. <i>Addiction Biology</i> , 2023, 28, .	1.4	1
1103	Aspekte der Behandlung straffälliger Menschen mit Suchtproblemen. , 2023, , 489-506.		0